C.R.C., c. 1041 Subsections 31(1) and (3) of the Legislation Revision and Consolidation Act, in force on June 1, 2009, provide as follows: C.R.C., ch. 1041 OFFICIAL STATUS OF CONSOLIDATIONS
... LAYOUT NOTE --- CARACTÈRE OFFICIEL DES CODIFICATIONS Les paragraphes 31(1) et (3) de la Loi sur la révision et la codification des textes législatifs, en vigueur le 1er juin 2009, prévoient ce qui suit : Codifications comme élément de preuve 31 (1) Tout exemplaire d’une loi codifiée ou d’un règlement codifié, publié par le ministre en vertu de la présente loi sur support papier ou sur support électronique, fait foi de cette loi ou de ce règlement et de son contenu. Tout exemplaire donné comme publié par le ministre est réputé avoir été ainsi publié, sauf preuve contraire. [...] Incompatibilité — règlements (3) Les dispositions du règlement d’origine avec ses modifications subséquentes enregistrées par le greffier du Conseil privé en vertu de la Loi sur les textes réglementaires l’emportent sur les dispositions incompatibles du règlement codifié publié par le ministre en vertu de la présente loi. MISE EN PAGE Les notes apparaissant auparavant dans les marges de droite ou de gauche se retrouvent maintenant en caractères gras juste au-dessus de la disposition à laquelle elles se rattachent. Elles ne font pas partie du texte, n’y figurant qu’à titre de repère ou d’information. NOTE Cette codification est à jour au 22 janvier 2025. Les dernières modifications sont entrées en vigueur le 5 juin 2024. Toutes modifications qui n’étaient pas en vigueur au 22 janvier 2025 sont énoncées à la fin de ce document sous le titre « Modifications non en vigueur ».
4 Authorized activities 5 Application for registration number Licensed Dealers 8 General 9.1 Senior person in charge 9.2 Qualified person in charge Amendment of Licence 12.1 Amendment 12.1 Modification Changes Requiring Prior Approval by Minister Changes Requiring Notice to Minister 14.3 Notice of cessation of activities Changes to Terms and Conditions of Licence 15 Addition of or modification to term or condition 15.1 Deletion of term or condition Suspension and Revocation of Licence 17 Revocation 20 Revocation 23 Revocation Identification 25 Sale to another licensed dealer 25.5 Sale to Minister 25.6 Written order Packaging and Transportation 26 Packaging — sale and provision 26.1 Transport Thefts, Losses and Suspicious Transactions 27 Protective measures 27.4 Partial protection against self-incrimination 27.5 Destruction at site 27.6 Destruction elsewhere than at site 27.7 Application for prior approval 28 Method of recording information 28.5 Annual report 29.1 Location 29.2 Quality of documents Pharmacists Record of Narcotics Received 32 Prohibition — pharmacist or practitioner named in notice 40 File by date and number 41 Providing information and assisting inspector 42 Loss or theft — report 44 Preparing narcotic — approval of formula 45 Written order Communication of Information by Minister to Licensing Authority 46 Contraventions by pharmacist Notice of Prohibition of Sale 47 Request by pharmacist 48 Notice by Minister 53 Restriction 54 Record of narcotics sold or provided Communication of Information by Minister to Licensing Authority 57 Contraventions by practitioner Notice of Prohibition of Sale 58 Request by practitioner 59 Notice by Minister 64 Providing information and assisting inspector 65 Selling, providing or administering narcotic General 68 Identification or analysis of narcotic 69 Records — person who is exempted or who has received a narcotic for the purpose of identification or analysis 70 Advertising 72 Notification of application for order of restoration 73 Communication of information by Minister to nursing statutory body 74 Exemption — member of police force TABLE OF PROVISIONS Interpretation 2 Definitions Possession 3 Authorized persons Test Kits 6 Issuance of registration number 7 Cancellation of registration number Authorized Activities Dealer’s Licences Preliminary Requirements 9 Eligible persons 9.3 Ineligibility Issuance of Licence 10 Application 10.1 Issuance 10.2 Validity 10.3 Refusal Renewal of Licence 11 Application 11.1 Renewal 11.2 Validity 11.3 Refusal 12 Application TABLE ANALYTIQUE Règlement sur les stupéfiants Définitions et interprétation 2 Définitions Possession 3 Personnes autorisées Nécessaires d’essai 4 Opérations autorisées 5 Numéro d’enregistrement — demande 6 Numéro d’enregistrement — attribution 7 Numéro d’enregistrement — annulation Distributeurs autorisés Opération autorisées 8 Exigences générales Licences de distributeurs autorisé Exigences préalables 9 Personnes admissibles 9.1 Responsable principal 9.2 Responsable qualifié 9.3 Inadmissibilité Délivrance d’une licence 10 Demande 10.1 Délivrance 10.2 Validité 10.3 Refus Renouvellement de la licence 11 Demande 11.1 Renouvellement 11.2 Validité 11.3 Refus Modification de la licence 12 Demande 12.2 Validity 12.3 Refusal 13 Application 13.1 Approval 13.2 Refusal 14 Prior notice 14.1 Notice — five days 14.2 Notice — 10 days 16 Suspension 17.1 Return of licence Import Permits 18 Application 18.1 Issuance 18.2 Validity 18.3 Return of permit 18.4 Refusal 18.5 Providing copy of permit 18.6 Declaration 19 Suspension 20.1 Return of permit Export Permits 21 Application 21.1 Issuance 21.2 Validity 21.3 Return of permit 21.4 Refusal 21.5 Providing copy of permit 21.6 Declaration 22 Suspension 23.1 Return of permit 24 Name Sale of Narcotics 25.1 Sale to pharmacist 25.2 Sale to practitioner 25.3 Provision to hospital employee 25.4 Sale to exempted person 25.7 Verbal order 27.1 Theft or loss — licences and permits 27.2 Theft or unexplainable loss — narcotics 27.3 Suspicious transaction Destruction of Narcotics 27.8 Approval Documents 28.1 Information — general 28.2 Verbal prescription narcotic 28.3 Explainable loss of narcotic 28.4 Destruction 29 Retention period 30 General information Sale of Narcotics 31 Restriction 33 Exception — notice of retraction 34 Verbal prescription narcotic 35 Provision to hospital 36 Low-dose codeine preparation 37 Maximum Quantity Records 38 Written order or prescription 39 Verbal order or prescription 40.1 Retention period General Obligations of Pharmacist 43 Loss or theft — protective measures Return or Emergency Sale 49 Notice of retraction Practitioners Administer, Prescribe or Sell Narcotics General Obligations of Practitioner 55 Requirements 60 Notice of retraction Hospitals 63 General obligations 67 Opium poppy SCHEDULE
Act means the Controlled Drugs and Substances Act. (Loi) advertisement includes any representation by any means for the purpose of promoting, directly or indirectly, the sale or other disposal of a narcotic. (publicité) common-law partner, in relation to an individual, means a person who is cohabiting with the individual in a conjugal relationship, having so cohabited for a period of at least one year. (conjoint de fait) competent authority means a public authority of a foreign country that is authorized under the laws of the country to approve the importation or exportation of narcotics into or from the country. (autorité compétente) compound includes a preparation. (composé) designated criminal offence means (a) an offence involving the financing of terrorism against any of sections 83.02 to 83.04 of the Criminal Code; (b) an offence involving fraud against any of sections 380 to 382 of the Criminal Code; (c) the offence of laundering proceeds of crime against section 462.31 of the Criminal Code; (d) an offence involving a criminal organization against any of sections 467.11 to 467.13 of the Criminal Code; or (e) a conspiracy or an attempt to commit, being an accessory after the fact in relation to, or any counselling destroy means, in respect of a narcotic, to alter or denature it to such an extent that its consumption is rendered impossible or improbable. (destruction) hospital means a facility (a) that is licensed, approved or designated by a province in accordance with the laws of the province to provide care or treatment to persons or animals suffering from any disorder of disease or illness; or (b) that is owned or operated by the Government of Canada or the government of a province and that provides health services. (hôpital) international obligation means an obligation in respect of a narcotic set out in a convention, treaty or other multilateral or bilateral instrument that Canada has ratified or to which Canada adheres. (obligation internationale) methadone includes the salts of methadone. (méthadone) midwife has the same meaning as in section 1 of the New Classes of Practitioners Regulations. (sage-femme) narcotic means (a) a controlled substance set out in the schedule; or (b) in respect of a midwife, nurse practitioner or podiatrist, a controlled substance set out in the schedule that the midwife, nurse practitioner or podiatrist may prescribe, possess or conduct an activity with, in accordance with sections 3 and 4 of the New Classes of Practitioners Regulations. (stupéfiant) nurse practitioner has the same meaning as in section 1 of the New Classes of Practitioners Regulations. (infirmier praticien) pharmacist means a person who is entitled under the laws of a province to practise pharmacy and who is practising pharmacy in that province. (pharmacien) podiatrist has the same meaning as in section 1 of the New Classes of Practitioners Regulations. (podiatre) prescription means an authorization given by a practitioner that a stated amount of a narcotic be dispensed for the person named in it or the animal identified in it. (ordonnance) Security Directive means the Directive on Physical Security Requirements for Controlled Substances and Drugs Containing Cannabis, as amended from time to time and published by the Government of Canada on its website. (Directive en matière de sécurité) senior person in charge means the individual designated under section 9.1. (responsable principal) test kit means a kit (a) that contains a narcotic and a reagent system or buffering agent; (b) that is used during the course of a chemical or analytical procedure to test for the presence or quantity of a narcotic for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose; and verbal prescription narcotic means a narcotic that is contained in medication that may be prescribed verbally and that has the following characteristics: (a) it contains two or more medicinal ingredients that are not narcotics, in a recognized therapeutic dose; (b) it is not intended for parenteral administration; and
LOI RÉGLEMENTANT CERTAINES DROGUES ET AUTRES SUBSTANCES Règlement sur les stupéfiants 1 [Abrogé, DORS/2019-169, art. 2] Définitions et interprétation Définitions 2 (1) Les définitions qui suivent s’appliquent au présent règlement. autorité compétente Organisme public d’un pays étranger qui est habilité, au titre des lois du pays, à consentir à l’importation ou à l’exportation de stupéfiants. (competent authority) composé Vise notamment les préparations. (compound) conjoint de fait La personne qui vit avec la personne en cause dans une relation conjugale depuis au moins un an. (common-law partner) destruction S’agissant d’un stupéfiant, le fait de l’altérer ou de le dénaturer au point d’en rendre la consommation impossible ou improbable. (destroy) diacétylmorphine (héroïne) Comprend les sels de diacétylmorphine. (diacetylmorphine (heroin)) Directive en matière de sécurité La Directive sur les exigences en matière de sécurité physique pour les substances désignées et les drogues contenant du cannabis, avec ses modifications successives, publiée par le gouvernement du Canada sur son site Web. (Security Directive) distributeur autorisé Titulaire d’une licence délivrée au titre de l’article 10.1. (licensed dealer) hôpital L’établissement, selon le cas : a) qui peut, au titre d’une licence, d’une autorisation ou d’une désignation délivrée par une province sous le régime de ses lois, fournir des soins ou des traitements aux personnes ou aux animaux atteints d’une maladie ou d’une affection; b) qui fournit des services de santé et qui soit appartient au gouvernement du Canada ou au in relation to, an offence referred to in any of paragraphs (a) to (d). (infraction désignée en matière criminelle) diacetylmorphine (heroin) includes the salts of diacetylmorphine. (diacétylmorphine (héroïne)) licensed dealer means the holder of a licence issued under section 10.1. (distributeur autorisé) gouvernement d’une province, soit est exploité par lui. (hospital) infirmier praticien S’entend au sens de l’article 1 du Règlement sur les nouvelles catégories de praticiens. (nurse practitioner) infraction désignée en matière criminelle S’entend des infractions suivantes : a) infraction relative au financement du terrorisme visée à l’un des articles 83.02 à 83.04 du Code criminel; b) infraction de fraude visée à l’un des articles 380 à 382 du Code criminel; c) infraction de recyclage des produits de la criminalité visée à l’article 462.31 du Code criminel; d) infraction relative à une organisation criminelle visée à l’un des articles 467.11 à 467.13 du Code criminel; e) tentative ou complot en vue de commettre une infraction visée à l’un des alinéas a) à d), complicité après le fait à son égard ou conseil en vue de la perpétrer. (designated criminal offence) Loi La Loi réglementant certaines drogues et autres substances. (Act) méthadone Comprend les sels de méthadone. (methadone) nécessaire d’essai Nécessaire qui a les caractéristiques suivantes : a) il contient d’une part un stupéfiant et d’autre part un réactif ou une substance tampon; b) il est utilisé dans un processus chimique ou analytique de dépistage ou de quantification d’un stupéfiant à des fins médicales, industrielles, éducatives, pour des travaux de laboratoire ou de recherche ou pour l’application ou l’exécution de la Loi; c) son contenu n’est pas destiné à être consommé par une personne ou un animal, ni à leur être administré, et il n’est pas susceptible de l’être. (test kit) obligation internationale Toute obligation relative à un stupéfiant prévue par une convention, un traité ou un autre instrument multilatéral ou bilatéral que le Canada a ratifié ou auquel il adhère. (international obligation) ordonnance À l’égard d’un stupéfiant, l’autorisation d’un praticien d’en dispenser une quantité déterminée qualified person in charge means the individual designated under subsection 9.2(1). (responsable qualifié) (c) the contents of which are not intended or likely to be consumed by, or administered to, a person or an animal. (nécessaire d’essai) (c) it does not contain diacetylmorphine (heroin), hydrocodone, methadone, oxycodone or pentazocine. (stupéfiant d’ordonnance verbale)
(a) requires the narcotic for their business or profession and is (i) a licensed dealer, (iii) a practitioner who is registered and entitled to practise in the province in which they possess the narcotic; (b) is a practitioner who is registered and entitled to practise in a province other than the province in which they possess the narcotic for emergency medical purposes only; (c) is a hospital employee or a practitioner in a hospital; (d) has obtained the narcotic for their own use (i) from a practitioner, (ii) in accordance with a prescription that was not issued or obtained in contravention of these Regulations, or (iii) from a pharmacist under section 36; (e) is a practitioner of medicine who received the narcotic under subsection 68(1) or (2) and their possession is for the purpose of providing or delivering it to a person referred to in subsection 68(3); (f) is an agent or mandatary of a practitioner of medicine who received the narcotic under subsection 68(1) and their possession is for the purpose of providing or delivering it to a person referred to in subsection 68(2); (g) is employed as an inspector, a member of the Royal Canadian Mounted Police, a police constable, a peace officer or a member of the technical or scientific staff of the Government of Canada, the government of a province or a university in Canada and their possession is in connection with that employment; (h) is not a practitioner of medicine referred to in paragraph (e) or an agent or mandatory referred to in paragraph (f), is exempted under section 56 of the Act with respect to the possession of that narcotic and their possession is for a purpose set out in the exemption; or (i) is the Minister.
[Repealed, SOR/2021-271, s. 3] SOR/85-184, s. 1; SOR/81-361, s. 1; SOR/85-88, s. 1; SOR/86-173, s. 1; SOR/88-275, s. 1(F); SOR/90-136, s. 1; SOR/93-227, s. 1; SOR/2003-154, s. 1; SOR/2004-237, s. 1; SOR/2010-223, s. 1; SOR/2013-119, s. 26; SOR/2013-172, s. 3; SOR/2015-121, s. 1; SOR/2016-230, ss. 48(F), 270; SOR/2016-239, s. 2; SOR/2018-141, s. 1; SOR/2019-169, s. 3; SOR/2021-271, s. 3.
A person is authorized to possess a narcotic if the person is acting as the agent or mandatory of any person who is authorized to possess it in accordance with any of paragraphs (1)(a) to (e), (h) and (i).
Possession Authorized persons (ii) a pharmacist, or Agent or mandatory Agent or mandatory — person referred to in paragraph (1)(g) SOR/85-588, s. 2; SOR/85-930, s. 2; SOR/97-227, s. 2; SOR/98-134, s. 1; SOR/2012-230, s. 15; SOR/2013-119, s. 202; SOR/2013-172, s. 4; SOR/2016-230, s. 23; SOR/2016-239, s. 3; SOR/2018-37, s. 1; SOR/2018-69, ss. 75, 76; SOR/2018-147, s. 2; SOR/2019-169, s. 3. Test Kits (i) the manufacturer’s name, (iii) the registration number; 2014, c. 20, s. 366(E); SOR/2019-169, s. 3. SOR/2018-69, s. 71; SOR/2019-169, s. 3. Issuance of registration number (iii) le numéro d’enregistrement; c) le nécessaire d’essai sera utilisé à des fins médicales, industrielles ou éducatives, pour des travaux de laboratoire ou de recherche ou pour l’application ou l’exécution de la loi. 2014, ch. 20, art. 366(A); DORS/2019-169, art. 3. Numéro d’enregistrement — demande 5 (1) Le fabricant d’un nécessaire d’essai peut obtenir un numéro d’enregistrement en présentant au ministre une demande qui contient les renseignements suivants : a) une description détaillée de la conception et de la fabrication du nécessaire d’essai; b) une description détaillée du stupéfiant et, le cas échéant, des autres substances que contient le nécessaire d’essai, ainsi que la description qualitative et quantitative de chacun des composants; c) une description de l’utilisation à laquelle est destiné le nécessaire d’essai. Signature et attestation
A person is authorized to possess a narcotic if (a) the person is acting as the agent or mandatory of a person who they have reasonable grounds to believe is a person referred to in paragraph (1)(g); and (b) their possession of the narcotic is for the purpose of assisting that person in the administration or enforcement of an Act or regulation. Authorized activities
La demande satisfait aux exigences suivantes : a) elle est signée et datée par la personne autorisée à cette fin par le demandeur; b) elle comprend une attestation de celle-ci portant qu’à sa connaissance, tous les renseignements fournis à l’appui de la demande sont exacts et complets. Renseignements et documents complémentaires
(a) a registration number has been issued for the test kit under section 6 and has not been cancelled under section 7; (b) the test kit bears, on its external surface, (ii) the trade name or trademark, and (c) the test kit will be used for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose. Application for registration number
Le demandeur fournit au ministre, au plus tard à la date précisée dans la demande écrite de celui-ci et à cet effet, tout renseignement ou document que le ministre juge nécessaire pour compléter l’examen de la demande du numéro d’enregistrement. DORS/2018-69, art. 71; DORS/2019-169, art. 3. Numéro d’enregistrement — attribution 6 Le ministre, au terme de l’examen de la demande de numéro d’enregistrement, attribue un numéro d’enregistrement précédé des lettres « TK » au nécessaire d’essai s’il établit que ce dernier satisfait à l’une des exigences ci-après et sera utilisé seulement à des fins médicales, industrielles ou éducatives, pour des travaux de laboratoire ou de recherche ou pour l’application ou l’exécution de la loi : a) il contient un stupéfiant et un agent d’adultération ou un dénaturant, mélangés de telle manière et en quantités, proportions ou concentrations telles que la SOR/81-22, s. 1; SOR/2019-169, s. 3. Cancellation of registration number SOR/2019-169, s. 3. [SOR/2004-237, s. 2] Authorized Activities Permit — import and export Opium poppy — production SOR/2004-237, s. 3; SOR/2013-119, s. 20; SOR/2016-123, s. 1; SOR/2016-230, ss. 264, 278; SOR/2018-147, s. 3; SOR/2019-169, s. 3.
(a) a detailed description of the design and construction of the test kit; (b) a detailed description of the narcotic and other substances, if any, contained in the test kit, including the qualitative and quantitative composition of each component; and (c) a description of the proposed use of the test kit. Signature and attestation
The application must (a) be signed and dated by the person authorized by the applicant for that purpose; and (b) include an attestation by that person that all of the information submitted in support of the application is correct and complete to the best of their knowledge. Additional information or document
The applicant must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.
Dealer’s Licences Preliminary Requirements Eligible persons (a) an individual who ordinarily resides in Canada; SOR/85-588, s. 3(F); SOR/2004-237, s. 4; SOR/2012-230, s. 17; SOR/2014-260, ss. 17, 27(F); SOR/2019-169, s. 3. SOR/2004-237, s. 4; SOR/2019-169, s. 3. SOR/2004-237, s. 4; SOR/2019-169, s. 3. Qualifications (a) they work at the site specified in the dealer’s licence; Responsable qualifié suppléant
(a) a narcotic and an adulterating or denaturing agent in such a manner, combination, quantity, proportion or concentration that the preparation or mixture has no significant drug abuse potential; or (b) such small quantities or concentrations of a narcotic as to have no significant drug abuse potential.
La personne qui demande une licence de distributeur autorisé peut désigner un individu à titre de responsable qualifié suppléant, le demandeur pouvant se désigner lui-même s’il est un individu, qui est autorisé à remplacer le responsable qualifié lorsque celui-ci est absent. Qualifications
(a) the test kit is removed from the market by the manufacturer; (b) the Minister has reasonable grounds to believe that the test kit is used or is likely to be used for any purpose other than a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose; or (c) the Minister has reasonable grounds to believe that the cancellation is necessary to protect public health or safety, including to prevent a narcotic from being diverted to an illicit market or use. Licensed Dealers General
Seul l’individu qui satisfait aux exigences ci-après peut être désigné à titre de responsable qualifié ou de responsable qualifié suppléant : a) il travaille à l’installation précisée dans la licence de distributeur autorisé; b) il est : (i) soit une personne autorisée ou, le cas échéant, inscrite et autorisée, par une autorité provinciale attribuant des licences en matière d’activités professionnelles ou par une association professionnelle au Canada, à exercer sa profession dans un domaine lié à ses fonctions, notamment pharmacien, praticien, technicien en pharmacie ou technicien de laboratoire, (ii) soit titulaire d’un diplôme, d’un certificat ou d’une attestation décerné par un établissement d’enseignement postsecondaire au Canada dans un domaine qui est lié à ses fonctions, notamment la pharmacie, la médecine, la dentisterie, la médecine vétérinaire, la pharmacologie, la chimie, la biologie, la réglementation pharmaceutique, la sécurité ou la gestion des chaînes d’approvisionnement, les techniques en pharmacie ou les techniques de laboratoire, (iii) soit titulaire d’un diplôme, d’un certificat ou d’une attestation décerné par un établissement d’enseignement étranger dans l’un des domaines visés au sous-alinéa (ii) et titulaire de l’une des attestations suivantes : (A) une attestation d’équivalence, au sens du paragraphe 73(1) du Règlement sur l’immigration et la protection des réfugiés, (B) une attestation d’équivalence délivrée par une institution ou une organisation chargée de faire de telles attestations et reconnue par une province; c) il possède des connaissances et une expérience relatives à l’utilisation et à la manutention des stupéfiants précisés dans la licence de distributeur autorisé pour exercer ses fonctions; d) il possède des connaissances suffisantes des dispositions de la Loi et du présent règlement qui s’appliquent aux activités précisées dans la licence de distributeur autorisé pour exercer ses fonctions. Exception SOR/2004-237, s. 4; SOR/2010-221, ss. 4, 18(F); SOR/2014-260, s. 18; SOR/2019-169, s. 3. Ineligibility SOR/2004-237, s. 4; SOR/2019-169, s. 3.
Qualified person in charge present
A licensed dealer may conduct an activity in relation to a narcotic at their site only if the qualified person in charge or an alternate qualified person in charge is present at the site.
A licensed dealer must obtain a permit in order to import or export a narcotic. Possession for export
A licensed dealer may possess a narcotic for the purpose of exporting it if they have obtained it in accordance with these Regulations.
A licensed dealer may cultivate, propagate or harvest opium poppy only for scientific purposes.
(b) a corporation that has its head office in Canada or operates a branch office in Canada; or (c) the holder of a position that includes responsibility for narcotics on behalf of the Government of Canada or of a government of a province, a police force, a hospital or a university in Canada. Senior person in charge
Qualified person in charge
Alternate qualified person in charge
Issuance of Licence Application (i) an individual, the individual’s name, (ii) soit s’est vu imposer, pour une infraction commise alors qu’il avait au moins quatorze ans et au moins de dix-huit ans, une peine plus longue que la peine maximale prévue par la peine spécifique, au sens du paragraphe 2(1) de la Loi sur le système de justice pénale pour les adolescents pour une telle infraction. DORS/2004-237, art. 4; DORS/2019-169, art. 3.
An applicant for a dealer’s licence may designate an individual as an alternate qualified person in charge, who is authorized to replace the qualified person in charge when that person is absent. The applicant may designate themself if the applicant is an individual.
Only an individual who meets the following requirements may be designated as a qualified person in charge or an alternate qualified person in charge: (b) they (i) are entitled or, if applicable, registered and entitled by a provincial professional licensing authority or a professional association in Canada and entitled to practise a profession that is relevant to their duties, such as pharmacist, practitioner, pharmacy technician or laboratory technician, (ii) hold a diploma, certificate or credential awarded by a post-secondary educational institution in Canada in a field or occupation that is relevant to their duties, such as pharmacy, medicine, dentistry, veterinary medicine, pharmacology, chemistry, biology, pharmacy technician, laboratory technician, pharmaceutical regulatory affairs or supply chain management or security, or (iii) hold a diploma, certificate or credential that is awarded by a foreign educational institution in a field or occupation referred to in subparagraph (ii) and hold (A) an equivalency assessment as defined in subsection 73(1) of the Immigration and Refugee Protection Regulations, or (B) an equivalency assessment issued by an organization or institution that is responsible for issuing equivalency assessments and is recognized by a province; (c) they have sufficient knowledge of and experience with the use and handling of the narcotics specified in the dealer’s licence to properly carry out their duties; and (d) they have sufficient knowledge of the provisions of the Act and these Regulations that are applicable to the activities specified in the dealer’s licence to properly carry out their duties.
An applicant for a dealer’s licence may designate an individual who does not meet any of the requirements of paragraph (3)(b) as a qualified person in charge or an alternate qualified person in charge if (a) no other individual working at the site meets those requirements; (b) those requirements are not necessary for the activities specified in the licence; and (c) the individual has sufficient knowledge — acquired from a combination of education, training or work experience — to properly carry out their duties.
(a) in respect of a designated substance offence or a designated criminal offence as defined in subsection 2(1) of the Cannabis Act, the individual (i) was convicted as an adult, or (ii) was a young person who received an adult sentence, as those terms are defined in subsection 2(1) of the Youth Criminal Justice Act; or (b) in respect of an offence committed outside Canada that, if committed in Canada, would have constituted a designated substance offence or a designated criminal offence as defined in subsection 2(1) of the Cannabis Act, (i) the individual was convicted as an adult, or (ii) was a young person who received an adult sentence, as those terms are defined in subsection 2(1) of the Youth Criminal Justice Act. (ii) if they committed the offence when they were at least 14 years old but less than 18 years old, the individual received a sentence that was longer than the maximum youth sentence, as that term is defined in subsection 2(1) of the Youth Criminal Justice Act, that could have been imposed under that Act for such an offence.
(a) if the licence is requested by (ii) a corporation, its corporate name and any other name registered with a province under which it intends to conduct the activities specified in its dealer’s licence or by which it intends to identify itself, and (iii) the holder of a position described in paragraph 9(c), the applicant’s name and the title of the position; (b) the municipal address, telephone number and, if applicable, the email address of the proposed site and, if different from the municipal address, its mailing address; (c) the name, date of birth, telephone number and email address of the proposed senior person in charge; (d) with respect to each of the proposed qualified person in charge and any proposed alternate qualified person in charge, (i) their name, date of birth, telephone number and email address, (ii) the title of their position at the site, (iii) the name and title of the position of their immediate supervisor at the site, (iv) if applicable, the profession they practise that is relevant to their duties, the name of the province that authorizes them to practise it and their authorization number, and (v) their education, training and work experience that are relevant to their duties; (e) the activities that are to be conducted and the narcotics in respect of which each of the activities is to be conducted; (f) if the licence is requested to manufacture or assemble a product or compound that contains a narcotic other than a test kit, a list that includes, for each product or compound, (i) the brand name of the product or the name of the compound, (ii) the drug identification number that is assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any, (iii) the name of the narcotic in the product or compound, (iv) the strength per unit of the narcotic in it, the number of units per package and the number of packages, (v) if it is to be manufactured or assembled by or for another licensed dealer under a custom order, the name, municipal address and licence number of the other licensed dealer, and (vi) if the applicant’s name appears on the label of the product or compound, a copy of the inner label, as defined in section A.01.010 of the Food and Drug Regulations; (g) if the licence is requested in order to produce a narcotic other than a product or compound that contains a narcotic, (ii) the quantity that the applicant expects to produce under their licence and the period during which that quantity would be produced, and (iii) if it is to be produced for another licensed dealer under a custom order, the name, municipal address and licence number of the other licensed dealer; (h) if the licence is requested for an activity that is not described in paragraph (f) or (g), the name of the narcotic for which the activity is to be conducted and the purpose of the activity; (i) a detailed description of the security measures in place at the site, determined in accordance with the Security Directive; and (j) a detailed description of the method for recording information that the applicant proposes to use for the purpose of section 28.
An application for a dealer’s licence must be accompanied by the following documents: (a) if the applicant is a corporation, a copy of (i) the certificate of incorporation or other constituting instrument, and (ii) any document filed with the province in which its site is located that states its corporate name and any other name registered with the province under which the applicant intends to conduct the activities specified in its dealer’s licence or by which it intends to identify itself; (b) individual declarations signed and dated by each of the proposed senior person in charge, and qualified person in charge and any proposed alternate qualified person in charge, attesting that the person is not ineligible for a reason specified in section 9.3; (c) a document issued by a Canadian police force in relation to each person referred to in paragraph (b), indicating whether, during 10 years before the day on which the application is submitted, the person was convicted as specified in subparagraph 9.3(a)(i) or received a sentence as specified in subparagraph 9.3(a)(ii); (d) if any of the persons referred to in paragraph (b) has ordinarily resided in a country other than Canada during the 10 years before the day on which the application is submitted, a document issued by a po- lice force of that country indicating whether in that pe- riod that person was convicted as specified in subpara- graph 9.3(b)(i) or received a sentence as specified in (e) declaration, signed and dated by the proposed se- nior person in charge, attesting that the proposed qualified person in charge and any proposed alternate qualified person in charge have the knowledge and ex- (f) if the proposed qualified person in charge or any proposed alternate qualified person in charge does not (ii) a detailed description of the education, training and work experience that is required under para- graph 9.2(4)(c), together with supporting evidence, such as a copy of a course transcript or an attesta- Signature and attestation
The application must (a) be signed and dated by the proposed senior person in charge; and (b) include an attestation by that person that (i) all of the information and documents submitted in support of the application are correct and com- plete to the best of their knowledge, and (ii) they have the authority to bind the applicant. Additional information and documents in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.
of the licence application, the Minister must issue a deal- er’s licence, with or without terms and conditions, that contains cence. (b) the name of the licensed dealer, their corporate name or the title of the position they hold; (c) the activities that are authorized and the names of the narcotics in respect of which each activity may be conducted; (e) the security level at the site, determined in accordance with the Security Directive; (g) the expiry date of the licence, which must be not later than three years after its effective date; (h) any terms and conditions that the Minister has reasonable grounds to believe are necessary to (i) ensure that an international obligation is respected, (ii) ensure conformity with the requirements associated with the security level that is referred to in paragraph (e), or (iii) reduce a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use; and (i) if the licensed dealer produces a narcotic, the quantity that they may produce and the authorized production period.
Délivrance d’une licence Demande 10 (1) La personne qui prévoit d’effectuer l’une des opérations visées à l’article 8 doit obtenir une licence de distributeur autorisé pour chaque installation où elle prévoit d’effectuer celle-ci en présentant au ministre une demande qui contient les renseignements suivants : a) les précisions ci-après à l’égard du demandeur : (i) s’agissant d’un individu, son nom, (ii) s’agissant d’une personne morale, sa dénomination sociale et toute autre dénomination enregistrée dans une province sous laquelle elle entend s’identifier ou sous laquelle elle entend effectuer les activités précisées dans la licence, (iii) s’agissant du titulaire d’un poste visé à l’alinéa 9(c), son nom et le titre de son poste; b) l’adresse municipale, le numéro de téléphone et, le cas échéant, l’adresse électronique de l’installation de même que, si elle diffère de l’adresse municipale, son adresse postale; c) les nom, numéro de téléphone et adresse électronique du responsable principal proposé ainsi que sa date de naissance; (i) the name of the narcotic, Documents (i) son nom, (ii) la quantité que le demandeur prévoit de produire en vertu de la licence et la période prévue pour la production, (iii) s’il est produit sur mesure aux termes d’une commande spéciale pour un autre distributeur autorisé, les nom, adresse municipale et numéro de licence de celui-ci; h) si la demande vise une opération qui n’est pas visée par les alinéas f) et g), le nom du stupéfiant qui fait l’objet de l’opération et le but de cette dernière; i) la description détaillée des mesures de sécurité mises en place à l’installation et établies conformément à la Directive en matière de sécurité; j) la description détaillée de la méthode de consignation des renseignements que le demandeur prévoit d’utiliser en application de l’article 28. Documents
La demande est accompagnée des documents suivants : a) dans le cas où le demandeur est une personne morale : (i) une copie de son certificat de constitution ou de tout autre acte constitutif, (ii) une copie de tout document déposé auprès de la province où se trouve son installation et qui indique sa dénomination sociale et tout autre nom enregistré dans la province sous lequel elle entend s’identifier ou effectuer les opérations précisées dans la licence; b) les déclarations individuelles signées et datées par le responsable principal, le responsable qualifié et tout responsable qualifié suppléant proposés attestant que le signataire n’est pas visé par l’article 9.3; c) à l’égard de chaque personne visée à l’alinéa b), un document délivré par un corps policier canadien précisant si, au cours des dix années précédant la présentation de la demande, elle a fait l’objet d’une condamnation visée au sous-alinéa 9.3a)(i) ou si elle a reçu une peine visée au sous-alinéa 9.3a)(ii); d) à l’égard de chaque personne visée à l’alinéa b) qui a résidé de façon habituelle dans un pays étranger au cours des dix années précédant la présentation de la demande, un document délivré par un corps policier subparagraph 9.3(b)(ii); perience required under paragraphs 9.2(3)(c) and (d); and meet the requirement of subparagraph 9.2(3)(b)(i), ei- ther (i) a copy of the person’s diploma, certificate or cre- dential referred to in subparagraph 9.2(3)(b)(ii) or (iii), or tion by the person who provided the training.
(a) the applicant may not apply for a licence under section 9; (b) during the 10 years before the day on which the licence application is submitted, the applicant has contravened (i) a provision of the Act, the Cannabis Act or their regulations, or (ii) a term or condition of a licence or permit issued to the applicant under any regulations made under the Act or issued to the applicant under the Cannabis Act or its regulations; (c) during the 10 years before the day on which the licence application is submitted, the proposed senior person in charge or qualified person in charge or any proposed alternate qualified person in charge was convicted as specified in subparagraph 9.3(a)(i) or (b)(i) or received a sentence as specified in subparagraph 9.3(a)(ii) or (b)(ii); (d) an activity for which the licence is requested would contravene an international obligation; (e) an activity for which the licence is requested is the cultivation, propagation or harvesting of opium poppy other than for scientific purposes; (f) the applicant does not have in place at the site the security measures set out in the Security Directive in respect of an activity for which the licence is requested; (g) the method referred to in paragraph 10(1)(j) does not permit the recording of information as required by section 28; (h) the applicant has not complied with the requirements of subsection 10(4) or the information or documents that they have provided are not sufficient to complete the review of the licence application; (i) the Minister has reasonable grounds to believe that the applicant has submitted false or misleading information or false or falsified documents in or in support of the licence application; (j) information received from a competent authority or the United Nations gives the Minister reasonable grounds to believe that the applicant has been involved in the diversion of a narcotic to an illicit market or use or has been involved in an activity that contravened an international obligation; or (k) the Minister has reasonable grounds to believe that the issuance of the licence would likely create a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use.
The applicant must, not later than the date specified SOR/2019-169, s. 3. Issuance de ce pays précisant si elle a fait l’objet d’une condam- nation visée au sous-alinéa 9.3b)(i) ou s’est vu imposer une peine visée au sous-alinéa 9.3b)(ii) dans ce pays au cours de cette période; e) une déclaration, signée et datée par le responsable principal, attestant que le responsable qualifié et tout responsable qualifié suppléant proposés ont les connaissances et l’expérience exigées aux alinéas
The Minister must not refuse to issue a licence under paragraph (1)(b) or (1)(c) if the applicant meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a narcotic from being diverted to an illicit market or use: (a) the applicant does not have a history of non-compliance with the Act, the Cannabis Act or their regulations; and (b) the applicant has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their regulations.
f) dans le cas où le responsable qualifié ou tout res- ponsable qualifié suppléant proposé ne satisfait pas à l’exigence visée au sous-alinéa 9.2(3)b)(i) : (i) une copie du diplôme, du certificat ou de l’attesta- tion visés aux sous-alinéas 9.2(3)b)(ii) ou (iii), (ii) une description détaillée des études, de la forma- tion et de l’expérience de travail visées à l’alinéa
Before refusing to issue a licence, the Minister must send the applicant a notice that sets out the Minister’s reasons and gives the applicant an opportunity to be heard.
une copie des relevés de notes ou de l’attestation faite par la personne en donnant la formation. Signature et attestation
Signature and attestation
La demande satisfait aux exigences suivantes : a) elle est signée et datée par le responsable principal proposé; b) elle comprend une attestation de celui-ci portant sur les faits suivants : (i) à sa connaissance, tous les renseignements et documents fournis à l’appui de la demande sont exacts et complets, (ii) il est habilité à lier le demandeur. Renseignements et documents complémentaires
The application must (a) be signed and dated by the senior person in charge of the site specified in the application; and (b) include an attestation by that person that (i) all of the information and documents submitted in support of the application are correct and complete to the best of their knowledge, and (ii) they have the authority to bind the licensed dealer. Additional information and documents
Le demandeur fournit au ministre, au plus tard à la date précisée dans la demande écrite de celui-ci à cet ef- fet, tout renseignement ou document que le ministre juge nécessaire pour compléter l’examen de la demande de li- DORS/2019-169, art. 3. Délivrance
The licensed dealer must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document Narcotic Control Regulations Licensed Dealers
de licence et sous réserve de l’article 10.3, délivre une li- cence de distributeur autorisé, avec ou sans conditions, qui contient les renseignements suivants : (a) the licence number; (d) the municipal address of the site at which the dealer may conduct the authorized activities; (f) the effective date of the licence; SOR/2019-169, s. 3. Validity SOR/2019-169, s. 3. Refusal Exceptions Notice SOR/2019-169, s. 3. Renewal of Licence Application Exceptions
Terms and conditions
Le ministre ne peut, dans les cas visés aux alinéas (1)b) ou c), refuser de délivrer la licence si le demandeur remplit les conditions ci-après, sauf s’il a des motifs raisonnables de croire que le refus est nécessaire pour protéger la sécurité ou la santé publiques, notamment pour prévenir le détournement d’un stupéfiant vers un marché ou un usage illicites : a) le demandeur n’a pas d’antécédents de contravention à la Loi, à la Loi sur le cannabis ou à leurs règlements; b) il a soit pris les mesures correctives nécessaires pour veiller à respecter la Loi, la Loi sur le cannabis et leurs règlements, soit signé un engagement à cet effet. Préavis
When renewing a dealer’s licence, the Minister may, if he or she has reasonable grounds to believe that it is necessary to do so, add a term or condition to it or modify or delete one in order to (a) ensure that an international obligation is respected; (b) ensure conformity with the requirements associated with the security level specified in the licence or the new level required as a result of the licence renewal; or (c) reduce a risk to public health or safety, including the risk of a substance being diverted to an illicit market or use.
Le ministre, avant de refuser de délivrer la licence, envoie au demandeur un préavis motivé l’informant qu’il peut présenter ses observations à cet égard. DORS/2019-169, art. 3. Renouvellement de la licence Demande 11 (1) Le distributeur autorisé présente au ministre, pour obtenir le renouvellement de sa licence de distributeur autorisé, une demande qui contient les renseignements et documents visés aux paragraphes 10(1) et (2). Signature et attestation
La demande satisfait aux exigences suivantes : a) elle est signée et datée par le responsable principal de l’installation visée par la licence renouvelée précisée dans la demande; b) elle comprend une attestation de celui-ci portant sur les faits suivants : (i) à sa connaissance, tous les renseignements et documents fournis à l’appui de la demande sont exacts et complets, (ii) il est habilité à lier le distributeur autorisé. Renseignements et documents complémentaires
(a) the licensed dealer may no longer apply for a licence under section 9; (b) during the 10 years before the day on which the renewal application is submitted, the licensed dealer has contravened (i) a provision of the Act, the Cannabis Act or their Regulations, or (ii) a term or condition of a licence or permit issued to the dealer under a regulation made under the Act or issued to the dealer under the Cannabis Act or its regulations; (c) during the 10 years before the day on which the renewal application is submitted, the proposed senior person in charge or qualified person in charge or any proposed alternate qualified person in charge was convicted as specified in subparagraph 9.3(a)(i) or (b)(i) or received a sentence as specified in subparagraph 9.3(a)(ii) or (b)(ii); (d) an activity for which the renewal is requested would contravene an international obligation; (e) an activity for which the licence is requested is the cultivation, propagation or harvesting of opium poppy other than for scientific purposes; (f) the licensed dealer does not have in place at the site the security measures set out in the Security Directive in respect of an activity for which the renewal is requested; (g) the method referred to in paragraph 10(1)(j) does not permit the recording of information as required by section 28; (h) the licensed dealer has not complied with the requirements of subsection 11(3) or the information or documents that they have provided are not sufficient to complete the review of the renewal application; (i) the Minister has reasonable grounds to believe that the licensed dealer has submitted false or misleading information or false or falsified documents in or in support of the renewal application; (j) information received from a competent authority or the United Nations gives the Minister reasonable grounds to believe that the licensed dealer has been involved in the diversion of a narcotic to an illicit market or use or has been involved in an activity that contravened an international obligation; or (k) the Minister has reasonable grounds to believe that the renewal of the licence would likely create a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use.
Le distributeur autorisé fournit au ministre, au plus tard à la date précisée dans la demande écrite de celui-ci Dealer’s Licences Renewal of Licence Sections 11.1-11.3 Renewal SOR/2019-169, s. 3. Validity SOR/2019-169, s. 3. Refusal SOR/2019-169, s. 3. Règlement sur les stupéfiants Distributeurs autorisés Licences de distributeurs autorisés Renouvellement de la licence
The Minister must not refuse to renew a licence under paragraph (1)(b) or (i) if the licensed dealer meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a narcotic from being diverted to an illicit market or use: (a) the licensed dealer does not have a history of non-compliance with the Act or the Cannabis Act or their regulations; and (b) the licensed dealer has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their regulations.
Renouvellement
Before refusing to renew a licence, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard. Amendment of Licence
Conditions
Signature and attestation
Le ministre peut, lorsqu’il renouvelle la licence du distributeur autorisé, ajouter toute condition à la licence, en modifier les conditions ou supprimer l’une de celles-ci s’il a des motifs raisonnables de le croire nécessaire pour atteindre l’une des fins suivantes : a) le respect d’une obligation internationale; b) la conformité aux exigences associées au niveau de sécurité précisé dans la licence ou à tout nouveau niveau qui s’impose à la suite du renouvellement; c) la réduction d’un risque d’atteinte à la sécurité ou à la santé publiques, notamment le risque de détournement d’un stupéfiant vers un marché ou un usage illicites. DORS/2019-169, art. 3. Validité
The application must (a) be signed and dated by the senior person in charge of the site specified in the application; and (b) include an attestation by that person that (i) all of the information and documents submitted in support of the application are correct and complete to the best of their knowledge, and (ii) they have the authority to bind the licensed dealer. Additional information and documents
DORS/2019-169, art. 3. Refus
The licensed dealer must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application. Amendment
a) le distributeur autorisé ne peut plus demander une licence en vertu de l’article 9; b) le distributeur autorisé a contrevenu, dans les dix années précédant la présentation de la demande de renouvellement : (i) soit à une disposition de la Loi, de la Loi sur le cannabis ou de leurs règlements, (ii) soit à une condition d’une licence ou d’un permis qui lui a été délivré en vertu d’un règlement pris en vertu de la Loi ou qui lui a été délivré en vertu de la Loi sur le cannabis ou de ses règlements; DORS/2019-169, art. 3. Exceptions Notice SOR/2019-169, s. 3. Application SOR/2013-119, s. 22; SOR/2016-230, s. 278; SOR/2018-147, s. 8; SOR/2019-169, s. 3. SOR/2019-169, s. 3. Validity SOR/2019-169, s. 3. Refusal ---
Terms and conditions
Conditions
When amending a dealer’s licence, the Minister may, if he or she has reasonable grounds to believe that it is necessary to do so, add a term or condition to it or modify or delete one in order to (a) ensure that an international obligation is respected; (b) ensure conformity with the requirements associated with the security level specified in the licence or the new level required as a result of the amendment; or (c) reduce a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use.
Le ministre peut, lorsqu’il modifie la licence du distributeur autorisé, ajouter toute condition à la licence, en modifier les conditions ou supprimer l’une de celles-ci s’il a des motifs raisonnables de le croire nécessaire pour atteindre l’une des fins suivantes : a) le respect d’une obligation internationale; b) la conformité aux exigences associées au niveau de sécurité précisé dans la licence ou à tout nouveau niveau qui s’impose à la suite de la modification; c) la réduction d’un risque d’atteinte à la sécurité ou à la santé publiques, notamment le risque de détournement d’un stupéfiant vers un marché ou un usage illicites. DORS/2019-169, art. 3. Validité
DORS/2019-169, art. 3. Refus
(a) an activity for which the amendment is requested would contravene an international obligation; (b) an activity for which the licence is requested is the cultivation, propagation or harvesting of opium poppy other than for scientific purposes; (c) the licensed dealer does not have in place at the site the security measures set out in the Security Directive in respect of an activity for which the amendment is requested; (d) the method referred to in paragraph 10(1)(j) does not permit the recording of information as required by section 28; (e) the licensed dealer has not complied with the requirements of subsection 12(3) or the information or documents that they have provided are not sufficient to complete the review of the amendment application; Modification (f) the Minister has reasonable grounds to believe that the licensed dealer has submitted false or misleading information or false or falsified documents in or in support of the amendment application; or (g) the Minister has reasonable grounds to believe that the amendment of the licence would likely create a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use.
a) l’une des opérations pour lesquelles la modification est demandée entraînerait la violation d’une obligation internationale; b) l’une des opérations pour lesquelles la modification est demandée est la culture, la multiplication ou la récolte de pavot à opium à des fins autres que scientifiques; c) le distributeur autorisé n’a pas mis en place à l’installation les mesures de sécurité prévues dans la Directive en matière de sécurité à l’égard d’une opération pour laquelle il demande la modification; d) la méthode visée à l’alinéa 10(1)j) ne permet pas la consignation des renseignements conformément à l’article 28; e) soit le distributeur autorisé ne s’est pas conformé aux exigences prévues au paragraphe 12(3), soit il s’y Exceptions Notice SOR/2019-169, s. 3. Application (a) a change affecting the security measures in place at the site specified in the dealer’s licence; (d) the replacement or addition of an alternate qualified person in charge. (i) the information specified in paragraph 10(1)(c), and (ii) the declaration specified in paragraph 10(2)(b) and the documents specified in paragraphs 10(2)(c) and (d); and (i) the information specified in paragraph 10(1)(d), and (ii) the declarations specified in paragraphs 10(2)(b) and (e) and the documents specified in paragraphs 10(2)(c), (d) and (f). SOR/2004-237, s. 6; SOR/2010-221, s. 8; SOR/2019-169, s. 3. Approval c) le remplacement du responsable qualifié; d) le remplacement ou l’adjonction de tout responsable qualifié suppléant. Renseignements et documents
The Minister must not refuse to amend a licence under paragraph (1)(f) if the licensed dealer meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a narcotic from being diverted to an illicit market or use: (a) the licensed dealer does not have a history of non-compliance with the Act, the Cannabis Act or their regulations; and (b) the licensed dealer has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their Regulations.
Le distributeur autorisé fournit au ministre, pour tout changement visé au paragraphe (1), ce qui suit : a) les précisions concernant la modification ayant une incidence sur les mesures de sécurité mises en place à l’installation précisée dans sa licence; b) s’agissant du responsable principal : (i) les renseignements visés à l’alinéa 10(1)c), (ii) la déclaration visée à l’alinéa 10(2)b) et les documents visés aux alinéas 10(2)c) et d); c) s’agissant du responsable qualifié ou d’un responsable qualifié suppléant : (i) les renseignements visés à l’alinéa 10(1)d), (ii) les déclarations visées aux alinéas 10(2)b) et e) ainsi que les documents visés aux alinéas 10(2)c), d) et f). Renseignements et documents complémentaires
Before refusing to amend a licence, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard. Changes Requiring Prior Approval by Minister
Le distributeur autorisé fournit au ministre, au plus tard à la date précisée dans la demande écrite de celui-ci à cet effet, tout renseignement ou document que le ministre juge nécessaire pour compléter l’examen de la demande d’approbation de changement. DORS/2004-237, art. 6; DORS/2010-221, art. 8; DORS/2019-169, art. 3. Approbation
(b) the replacement of the senior person in charge; (c) the replacement of the qualified person in charge; or Information and documents
Conditions
The licensed dealer must provide the Minister with the following with respect to a change referred to in subsection (1): (a) in the case of a change affecting the security measures in place at the site specified in the dealer’s licence, details of the change; (b) in the case of the senior person in charge, (c) in the case of the qualified person in charge or an alternate qualified person in charge, Additional information and documents
Le ministre peut, lorsqu’il approuve le changement, ajouter toute condition à la licence du distributeur autorisé, en modifier les conditions ou supprimer l’une de celles-ci s’il a des motifs raisonnables de le croire nécessaire pour atteindre l’une des fins suivantes : a) le respect d’une obligation internationale; SOR/2010-221, s. 8; SOR/2014-260, s. 21; SOR/2019-169, s. 3. Refusal Exceptions Notice SOR/2010-221, s. 8; SOR/2019-169, s. 3. Prior notice SOR/2004-237, s. 7; SOR/2019-169, s. 3. Notice — five days SOR/2019-169, s. 3. Notice — 10 days SOR/2019-169, s. 3. Content of notice Update SOR/2019-169, s. 3. Notice Urgent circumstances Urgent circumstances — notice SOR/2004-237, s. 8; SOR/2019-169, s. 3. Notice SOR/2019-169, s. 3. Suspension Notice Reinstatement of licence SOR/2004-237, s. 9; SOR/2010-221, s. 9; SOR/2019-169, s. 3. (d) the licensed dealer does not take the corrective measures specified in an undertaking or notice; Exceptions Notice SOR/2019-169, s. 3. Return of licence SOR/2019-169, s. 3. Import Permits Application SOR/2019-169, s. 3. Issuance (a) the permit number; (b) the information set out in subsection 18(1); (d) the expiry date of the permit, being the earlier of (ii) the expiry date of the dealer’s licence; and SOR/2019-169, s. 3. Validity (a) the expiry date set out in the permit, a) elle est signée et datée par le responsable qualifié ou un responsable qualifié suppléant; b) elle comprend une attestation de celui-ci portant qu’à sa connaissance, tous les renseignements fournis à l’appui de la demande sont exacts. Renseignements et documents complémentaires
The licensed dealer must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.
Le distributeur autorisé fournit au ministre, au plus tard à la date précisée dans la demande écrite de celui-ci à cet effet, tout renseignement ou document que le ministre juge nécessaire pour compléter l’examen de la demande de permis d’importation. DORS/2019-169, art. 3. Délivrance
Terms and conditions
a) le numéro du permis; b) les renseignements visés au paragraphe 18(1); c) la date de prise d’effet du permis; d) la date d’expiration du permis, qui correspond à celle des dates ci-après qui est antérieure aux autres : (i) la date précisée par le ministre, qui ne peut être postérieure aux cent quatre-vingts jours suivant sa date de prise d’effet, (ii) la date d’expiration de la licence du distributeur autorisé; e) toute condition que le ministre estime nécessaire, sur le fondement de motifs raisonnables, pour atteindre l’une des fins suivantes : (i) le respect d’une obligation internationale, (ii) la réduction d’un risque d’atteinte à la sécurité ou à la santé publiques, notamment le risque de détournement d’un stupéfiant vers un marché ou un usage illicites. DORS/2019-169, art. 3. Validité
When approving a change, the Minister may, if he or she has reasonable grounds to believe that it is necessary to do so, add a term or condition to the licence or modify or delete one in order to (a) ensure that an international obligation is respected; (b) ensure conformity with the requirements associated with the security level specified in the licence; or (c) reduce a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use.
a) la date d’expiration qui y est indiquée; SOR/2019-169, s. 3. Return of permit SOR/2019-169, s. 3. Refusal Notice SOR/2019-169, s. 3. Providing copy of permit SOR/2019-169, s. 3. Declaration SOR/2019-169, s. 3. Suspension Notice Reinstatement of permit SOR/2004-237, s. 10; SOR/2010-221, s. 10; SOR/2019-169, s. 3. Exceptions Notice SOR/2019-169, s. 3. Return of permit SOR/2019-169, s. 3. Export Permits Application Export Permits
(a) during the 10 years before the day on which the application for approval of the change is submitted, the proposed senior person in charge or qualified person in charge or any proposed alternate qualified person in charge was convicted as specified in subparagraph 9.3(a)(i) or (b)(i) or received a sentence as specified in subparagraph 9.3(a)(ii) or (b)(ii); (b) the licensed dealer has not complied with the requirements of subsection 13(3) or the information or documents they have provided are not sufficient to complete the review of the application for approval of the change; (c) the Minister has reasonable grounds to believe that the licensed dealer has submitted false or misleading information or false or falsified documents in or in support of the application for approval of the change; or (d) the Minister has reasonable grounds to believe that the change would likely create a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use.
(d) the name and municipal address of the importer in the country of final destination; Règlement sur les stupéfiants Distributeurs autorisés Permis d’exportation
The Minister must not refuse to approve a change under paragraph (1)(c) if the licensed dealer has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their regulations, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a narcotic from being diverted to an illicit market or use.
(ii) s’agissant d’un sel, son nom, (iii) sa quantité, (iv) s’agissant d’une matière première, son degré de pureté et son contenu anhydre; c) si le stupéfiant est contenu dans un produit qu’il prévoit d’exporter, les précisions ci-après concernant ce produit : (i) sa marque nominative, (ii) l’identification numérique qui lui a été attribuée aux termes de l’article C.01.014.2 du Règlement sur les aliments et drogues, s’il y a lieu, (iii) la concentration du stupéfiant qu’il contient dans chacune de ses unités, le nombre d’unités par emballage et le nombre d’emballages; d) les nom et adresse municipale, dans le pays de destination finale, de l’importateur; e) le nom du bureau de douane où est prévue l’exportation; f) les modes de transport prévus et chaque pays de transit ou de transbordement prévu; g) une copie du permis d’importation délivré par l’autorité compétente du pays de destination finale précisant le nom de l’importateur et l’adresse municipale de son installation située dans ce pays. Signature et attestation
Before refusing to approve a change, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard in respect of them. Changes Requiring Notice to Minister
La demande satisfait aux exigences suivantes : a) elle est signée et datée par le responsable qualifié ou un responsable qualifié suppléant; b) elle comprend une attestation de celui-ci portant sur les faits suivants : (i) à sa connaissance, l’exportation prévue ne contrevient à aucune règle de droit du pays de destination finale, de tout pays de transit ou de tout pays de transbordement, (ii) à sa connaissance, tous les renseignements et documents fournis à l’appui de la demande sont exacts et complets. SOR/2019-169, s. 3. Issuance (a) the permit number; (b) the information set out in paragraphs 21(1)(a) to (f); (d) the expiry date of the permit, being the earliest of (ii) the expiry date of the dealer’s licence, and SOR/2019-169, s. 3. Validity (a) the expiry date set out in the permit, Export Sections 21.2-21.4 SOR/2019-169, s. 3. Return of permit SOR/2019-169, s. 3. Refusal Export Permits Sections 21.4-22 Notice SOR/2019-169, s. 3. Providing copy of permit SOR/2019-169, s. 3. Declaration SOR/2019-169, s. 3. Suspension Notice Reinstatement of permit SOR/2019-169, s. 3. Exceptions Notice SOR/85-588, s. 4(E); SOR/2019-169, s. 3. Return of permit SOR/2019-169, s. 3. Name SOR/78-145, s. 3; SOR/85-588, s. 5; SOR/85-930, s. 2; SOR/99-144, s. 2; SOR/2004-237, s. 11; SOR/2010-221, s. 15; SOR/2012-230, s. 18; SOR/2013-119, s. 20; SOR/2013-172, s. 5; SOR/2014-120, s. 22; SOR/2016-230, s. 26; SOR/2016-239, s. 4; SOR/2018-37, s. 2; SOR/2018-147, s. 9; SOR/2019-169, s. 3. Sale of Narcotics SOR/85-588, s. 6(E); SOR/85-930, s. 4; SOR/2003-134, s. 2; SOR/2019-169, s. 3. Sale to pharmacist Retraction SOR/2019-169, s. 3. Sale to practitioner Exception — heroin (a) a practitioner of medicine; SOR/2019-169, s. 3. Provision to hospital employee Exception — heroin SOR/2019-169, s. 3. Sale to exempted person SOR/2019-169, s. 3. SOR/2019-169, s. 3. SOR/2019-169, s. 3. Verbal order Receipt SOR/2019-169, s. 3. Exception SOR/2003-134, s. 2; SOR/2019-169, s. 3. Exception SOR/2019-169, s. 3. SOR/85-184, s. 4; SOR/85-588, s. 7; SOR/85-909, s. 5; SOR/99-124, s. 3; SOR/2004-237, s. 12; SOR/2010-222, s. 12; SOR/2012-230, s. 19; SOR/2013-119, s. 20; SOR/2013-211, s. 6; SOR/2014-260, ss. 22(E), 32(F); SOR/2016-239, s. 5; SOR/2018-37, s. 3; SOR/2018-147, s. 10; SOR/2019-169, s. 3. Theft or loss — licences and permits SOR/2019-169, s. 3. Theft or unexplainable loss — narcotics SOR/2019-169, s. 3. SOR/2019-169, s. 3. Suspicious transaction Good faith SOR/2019-169, s. 3. SOR/2019-169, s. 3. Destruction of Narcotics SOR/2019-169, s. 3. Destruction of Narcotics Sections 27.6-27.7 SOR/2019-169, s. 3. (d) a brief description of the method of destruction; Règlement sur les stupéfiants Distributeurs autorisés Destruction de stupéfiants
(a) manufacturing or assembling a product or compound that is not set out in the most recent version of the list referred to in paragraph 10(1)(f) that has been submitted to the Minister; or (b) making a change to a product or compound that is set out in the list, if the change affects any of the information that has previously been submitted. Information and list
c) la destruction est effectuée par une personne travaillant pour une entreprise spécialisée dans la destruction de marchandises dangereuses et en présence d’une autre personne travaillant pour cette entreprise; d) la destruction est effectuée selon une méthode conforme à la législation fédérale, provinciale et municipale sur la protection de l’environnement applicable au lieu de destruction; e) dès la destruction terminée, la personne qui l’a effectuée fournit au distributeur autorisé une déclaration datée qui atteste que le stupéfiant a été complètement détruit et qui contient les renseignements suivants : (i) l’adresse municipale du lieu où la destruction a été effectuée, (ii) le nom et la quantité du stupéfiant et, le cas échéant, la marque nominative et la quantité du produit qui en contenait ou le nom et la quantité du composé qui en contenait, (iii) la méthode de destruction, (iv) la date de la destruction, (v) les nom en lettres moulées et signature de cette personne ainsi que de l’autre personne présente lors de la destruction. DORS/2019-169, art. 3. Demande d’approbation préalable
The notice must contain the information referred to in paragraph 10(1)(f) that is necessary to update the list and be accompanied by the revised version of the list.
a) ses nom, adresse municipale et numéro de licence de distributeur autorisé; b) la date prévue de la destruction; c) l’adresse municipale du lieu où la destruction sera effectuée; d) une brève description de la méthode de destruction; e) si la destruction doit être effectuée à l’installation précisée dans sa licence, le nom des personnes proposées pour l’application de l’alinéa 27.5b) et des renseignements établissant que celles-ci remplissent les conditions visées à cet alinéa; SOR/2019-169, s. 3. Approval (d) the narcotic or a portion of it is required for the purposes of a criminal or administrative investigation. f) le nom du stupéfiant et, le cas échéant, la marque nominative du produit qui en contient ou le nom du composé qui en contient; g) la forme et la quantité soit du stupéfiant, soit du produit ou du composé qui en contient et, le cas échéant, la concentration du stupéfiant contenu dans chaque unité, le nombre d’unités par emballage et le nombre d’emballages. Signature et attestation
La demande satisfait aux exigences suivantes : a) elle est signée et datée par le responsable qualifié ou un responsable qualifié suppléant; b) elle comprend une attestation de celui-ci portant sur les faits suivants : (i) la méthode de destruction prévue est conforme à la législation fédérale, provinciale et municipale sur la protection de l’environnement applicable au lieu de destruction, (ii) à sa connaissance, tous les renseignements et documents fournis à l’appui de la demande sont exacts et complets. Renseignements et documents complémentaires
(a) a person ceases to act as the senior person in charge; or (b) the licensed dealer ceases to manufacture or assemble a product or compound that is set out in the most recent version of the list referred to in paragraph 10(1)(f) that has been submitted to the Minister. Information and list
Le distributeur autorisé fournit au ministre, au plus tard à la date précisée dans la demande écrite de celui-ci à cet effet, tout renseignement ou document que le ministre juge nécessaire pour compléter l’examen de la demande d’approbation. DORS/2019-169, art. 3. Approbation
A notice submitted under paragraph (1)(b) must specify which information referred to in paragraph 10(1)(f) is being changed and be accompanied by the revised version of the list. Notice of cessation of activities
a) si la destruction doit être effectuée à l’installation précisée dans la licence du distributeur autorisé, les personnes proposées pour l’application de l’alinéa 27.5b) ne remplissent pas les conditions visées à cet alinéa; b) le ministre a des motifs raisonnables de croire que le stupéfiant ne serait pas détruit; c) le ministre a des motifs raisonnables de croire que le distributeur autorisé a fourni, dans sa demande d’approbation ou à l’appui de celle-ci, des renseignements faux ou trompeurs ou des documents faux ou falsifiés; d) le stupéfiant ou une partie de celui-ci est requis aux fins d’une enquête criminelle ou administrative. SOR/2019-169, s. 3. Documents SOR/96-507, s. 1; SOR/2004-237, s. 13; SOR/2010-221, s. 12; SOR/2017-18, s. 24; SOR/2019-169, s. 3. Information — general d) le stupéfiant est, en tout ou en partie, nécessaire dans le cadre d’une enquête criminelle, administrative ou préliminaire, d’un procès ou d’une autre procédure engagée sous le régime d’une loi ou de ses règlements; e) le ministre a des motifs raisonnables de croire que l’approbation risquerait vraisemblablement de porter atteinte à la sécurité ou à la santé publiques, notamment en raison du risque de détournement du stupéfiant vers un marché ou un usage illicites. DORS/2019-169, art. 3. Documents Méthode de consignation 28 Le distributeur autorisé qui consigne des renseignements en application du présent règlement le fait selon une méthode qui en permet la vérification à tout moment. DORS/96-507, art. 1; DORS/2004-237, art. 13; DORS/2010-221, art. 12; DORS/2017-18, art. 24; DORS/2019-169, art. 3. Renseignements généraux
a) le nom, la forme et la quantité de tout stupéfiant qu’il commande, le nom de la personne qui fait la commande pour son compte et la date de la commande; b) le nom, la forme et la quantité de tout stupéfiant qu’il reçoit ainsi que les nom et adresse municipale de la personne qui le lui a vendu ou fourni et la date de réception; c) s’agissant d’un stupéfiant qu’il vend ou fournit, les précisions ci-après le concernant : (i) la marque nominative du produit ou le nom du composé contenant le stupéfiant et le nom de celui-ci, (ii) l’identification numérique qui a été attribuée au produit aux termes de l’article C.01.014.2 du Règlement sur les aliments et drogues, s’il y a lieu, (iii) la forme et la quantité du stupéfiant ainsi que, le cas échéant, la concentration du stupéfiant contenu dans chaque unité, le nombre d’unités par emballage et le nombre d’emballages, (iv) les nom et adresse municipale de la personne à laquelle il l’a vendu ou fourni, (v) la date de la vente ou de la fourniture; SOR/2019-169, s. 3. Verbal prescription narcotic SOR/2019-169, s. 3. Explainable loss of narcotic (d) the explanation for the loss. SOR/2019-169, s. 3. Destruction (a) the municipal address of the place of destruction; (d) the date of destruction. SOR/2019-169, s. 3. SOR/2019-169, s. 3. SOR/2019-169, s. 3. Retention period SOR/2019-169, s. 3. SOR/2019-169, s. 3. Documents Sections 29-31 SOR/2019-169, s. 3. [SOR/2019-169, s. 4] General information SOR/85-588, s. 8; SOR/2013-119, s. 211; SOR/2016-230, s. 267; SOR/2018-147, s. 11. Sale of Narcotics [SOR/2019-169, s. 5] Règlement sur les stupéfiants Distributeurs autorisés Documents
The notice must be signed and dated by the senior person in charge and contain the following information: (a) the expected date of the cessation of activities at the site; (b) a description of the manner in which any remaining narcotics on the site as of that date will be disposed of by the licensed dealer, including (i) if some or all of them will be sold or provided to another licensed dealer that will be conducting activities at the same site, the name of that dealer, (ii) if some or all of them will be sold or provided to another licensed dealer that will not be conducting activities at the same site, the name of that dealer and the municipal address of their site, and (iii) if some or all of them will be destroyed, the date on which and the municipal address of the location at which the destruction is to take place; (c) the municipal address of the location at which the licensed dealer’s documents will be kept after activities have ceased; and (d) the name, municipal address, telephone number and, if applicable, the email address of a person who the Minister may contact for further information after activities have ceased.
Caractéristiques des documents
After having ceased to conduct the activities, the licensed dealer must submit to the Minister a detailed update of the information referred to in subsection (2) if it differs from what was set out in the notice. The update must be signed and dated by the senior person in charge. Changes to Terms and Conditions of Licence Addition of or modification to term or condition
DORS/2019-169, art. 3. Pharmaciens Consignation de stupéfiants reçus [DORS/2019-169, art. 4] Renseignements généraux 30 Le pharmacien qui reçoit un stupéfiant d’un distributeur autorisé consigne immédiatement dans un cahier, un registre ou autre dossier réservé à cette fin les données suivantes : a) le nom et la quantité du stupéfiant qu’il a reçu; b) la date à laquelle il l’a reçu; et c) le nom et l’adresse de la personne de qui il a reçu ledit stupéfiant. DORS/85-588, art. 8; DORS/2013-119, art. 211; DORS/2016-230, art. 267; DORS/2018-147, art. 11. Vente de stupéfiants [DORS/2019-169, art. 5] 31 (1) Il est interdit au pharmacien de vendre ou de fournir un stupéfiant si ce n’est en conformité avec le présent article et les articles 34 à 36 et 45. Commande ou ordonnance écrites et exemption
(a) ensure that an international obligation is respected; (b) ensure conformity with the requirements associated with the security level specified in the licence; or (c) reduce a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use.
Le pharmacien peut vendre ou fournir un stupéfiant aux personnes suivantes : a) toute personne qui bénéficie d’une exemption en vertu de l’article 56 de la Loi relativement à la possession de ce stupéfiant; b) sauf s’il s’agit de diacétylmorphine (héroïne), toute personne s’il a reçu une commande ou ordonnance écrites à cet effet, lesquelles doivent être signées et datées par un praticien, et s’il a vérifié la signature de ce praticien lorsqu’il ne la reconnaît pas; c) s’agissant de diacétylmorphine (héroïne), toute personne s’il a reçu une commande ou ordonnance écrites à cet effet, lesquelles doivent être signées et datées par un médecin ou un infirmier praticien, et s’il a vérifié la signature de ce praticien lorsqu’il ne la reconnaît pas. Sale of Narcotics (2.1) [Repealed, SOR/2019-169, s. 6] Methadone (d) a practitioner.
Before adding a term or condition to a licence or modifying one, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.
[Repealed, SOR/2018-147, s. 12] SOR/85-588, s. 10(E); SOR/2003-134, s. 3; SOR/2019-169, s. 7. Règlement sur les stupéfiants Pharmaciens Vente de stupéfiants (2.1) [Abrogé, DORS/2019-169, art. 6] Méthadone
Despite subsection (2), the Minister may add a term or condition to a licence or modify one without prior notice if the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a narcotic from being diverted to an illicit market or use.
Le pharmacien peut vendre ou fournir de la méthadone aux personnes ci-après, en plus des personnes mentionnées au paragraphe (2) : a) un distributeur autorisé; b) un autre pharmacien; c) un employé d’un hôpital; d) un praticien.
The addition or modification of a term or condition that is made under subsection (3) takes effect as soon as the Minister sends the licensed dealer a notice that (a) sets out the reasons for the addition or modification; (b) gives the dealer an opportunity to be heard; and (c) if applicable, specifies the corrective measures that must be carried out and the date by which they must be carried out. Deletion of term or condition
[Abrogé, DORS/2018-147, art. 12] Interdiction — pharmacien ou praticien nommé dans un avis 32 Sous réserve de l’article 33 et nonobstant les paragraphes 31(2) et (3) et les articles 34 à 36, il est interdit à tout pharmacien de poser l’un des actes suivants : a) vendre ou fournir un stupéfiant, autre qu’un stupéfiant d’ordonnance verbale, au pharmacien nommé dans un avis donné par le ministre selon l’alinéa 48(1)a); b) vendre ou fournir un stupéfiant d’ordonnance verbale, autre qu’une préparation visée à l’article 36, au pharmacien nommé dans un avis donné par le ministre selon l’alinéa 48(1)b); c) vendre ou fournir une préparation visée à l’article 36 au pharmacien nommé dans un avis donné par le ministre selon l’alinéa 48(1)c); d) dispenser, vendre ou fournir un stupéfiant, autre qu’un stupéfiant d’ordonnance verbale, au praticien nommé dans un avis donné par le ministre selon le paragraphe 59(1) ou exécuter une commande ou une ordonnance d’un stupéfiant, autre qu’un stupéfiant d’ordonnance verbale, faite par le praticien nommé dans un tel avis; e) dispenser, vendre ou fournir un stupéfiant d’ordonnance verbale au praticien nommé dans un avis donné par le ministre selon le paragraphe 59(1) ou exécuter une commande ou une ordonnance d’un stupéfiant. Exception — notice of retraction SOR/2003-134, s. 3; SOR/2019-169, s. 8(F). Verbal prescription narcotic SOR/85-588, s. 11; SOR/85-930, s. 6; SOR/2019-169, s. 9. Provision to hospital (a) the pharmacist in charge of the hospital’s pharmacy; Signature SOR/85-588, s. 12; SOR/99-124, s. 15; SOR/2004-237, s. 15; SOR/2018-37, s. 5; SOR/2019-169, s. 10. Low-dose codeine preparation SOR/78-154, s. 6; SOR/85-588, s. 13; SOR/2004-237, s. 16; SOR/2012-230, s. 21. Maximum Quantity SOR/81-361, s. 3; SOR/2019-169, s. 11. Records Written order or prescription (d) the name, form and quantity of the narcotic; (f) the number assigned to the order or prescription. SOR/82-1073, s. 1; SOR/85-588, s. 14(E); SOR/2004-237, s. 17; SOR/2019-169, s. 11. Verbal order or prescription (d) in accordance with the manner in which it is specified in the order or prescription, the name and quantity of the verbal prescription narcotic or the narcotic and the other medicinal ingredients contained in it; SOR/85-588, s. 15; SOR/2004-237, s. 18; SOR/2019-169, s. 11. SOR/85-588, s. 16; SOR/2019-169, s. 11. Retention period SOR/2019-169, s. 11. General Obligations of Pharmacist [SOR/2019-169, s. 12] 41 A pharmacist shall (d) permit an inspector to check all stocks of narcotics on his premises. Loss or theft — protective measures SOR/81-361, s. 4; SOR/85-588, s. 17. Record — preparation Definition of prepare [SOR/2019-169, s. 13] Return or Emergency Sale Record SOR/86-882, s. 1; SOR/2003-134, s. 4; SOR/2010-221, s. 17; SOR/2013-119, s. 214; SOR/2016-230, s. 278; SOR/2018-147, s. 13; SOR/2019-169, s. 14. SOR/2003-134, s. 4. (a) a narcotic, other than a verbal prescription narcotic; Circumstances requiring a notice (B) soit que l’autorité a des motifs raisonnables de croire que le pharmacien exerce dans cette province sans autorisation. DORS/86-882, art. 1; DORS/2003-134, art. 4; DORS/2010-221, art. 17; DORS/2013-119, art. 214; DORS/2016-230, art. 278; DORS/2018-147, art. 13; DORS/2019-189, art. 14.
Recipients Other circumstances Règlement sur les stupéfiants Pharmaciens Avis d’interdiction de vente
The deletion takes effect as soon as the Minister sends the licensed dealer a notice to that effect. Suspension and Revocation of Licence
et l’autorité a demandé au ministre par écrit d’envoyer l’avis; c) il a été condamné pour une infraction désignée ou pour une contravention au présent règlement. Destinataires
Les destinataires de l’avis sont les suivants : a) tous les distributeurs autorisés; b) les pharmacies de la province où le pharmacien nommé dans l’avis, d’une part, est autorisé en vertu des lois de celle-ci à exercer sa profession et, d’autre part, l’y exerce; c) l’autorité provinciale attributive de licences en matière d’activités professionnelles de la province où le pharmacien nommé dans l’avis est autorisé à exercer; d) les pharmacies d’une province adjacente qui pourraient exécuter une commande faite par le pharmacien nommé dans l’avis; e) l’autorité provinciale attributive de licences en matière d’activités professionnelles d’une autre province qui en a fait la demande par écrit au ministre. Autres cas
The suspension takes effect as soon as the Minister sends the licensed dealer a notice that (a) sets out the reasons for the suspension; (b) gives the dealer an opportunity to be heard; and (c) if applicable, specifies the corrective measures that must be carried out and the date by which they must be carried out.
Le ministre peut envoyer l’avis visé au paragraphe (1) aux destinataires visés au paragraphe (3) s’il a pris les mesures prévues au paragraphe (5) et s’il a des motifs raisonnables de croire que le pharmacien nommé dans l’avis se trouve dans l’un des cas suivants : a) il a contrevenu à une disposition de la Loi ou du présent règlement; b) il s’est administré à plus d’une reprise un stupéfiant d’ordonnance verbale obtenu d’une façon non conforme aux pratiques pharmaceutiques reconnues; c) il s’est administré à plus d’une reprise un stupéfiant d’ordonnance verbale autre qu’une préparation mentionnée à l’article 36 obtenu d’une façon non conforme aux pratiques pharmaceutiques reconnues; d) il a, à plus d’une reprise, fourni ou administré un stupéfiant d’ordonnance verbale autre qu’un stupéfiant d’ordonnance verbale à son époux ou conjoint de fait, à son père, à sa mère ou à son enfant, y compris un enfant adopté de fait, d’une façon non conforme aux pratiques pharmaceutiques reconnues; Sections 48-49 Measures before sending notice SOR/2003-134, s. 4; SOR/2010-221, ss. 17, 18(F); SOR/2013-119, s. 215; SOR/2016-230, s. 278; SOR/2018-147, art. 14; DORS/2019-169, s. 15. Notice of retraction Règlement sur les stupéfiants Pharmaciens Avis d’interdiction de vente
The Minister must reinstate the licence if the Minister has reasonable grounds to believe that the suspension is no longer necessary. Revocation
e) il a, à plus d’une reprise, fourni ou administré un stupéfiant d’ordonnance verbale autre qu’une préparation mentionnée à l’article 36 à son époux ou conjoint de fait, à son père, à sa mère ou à son enfant, y compris un enfant adopté de fait, d’une façon non conforme aux pratiques pharmaceutiques reconnues; f) il est dans l’impossibilité de rendre compte de la quantité d’un stupéfiant dont il avait la responsabilité en application du présent règlement. Mesures préalables
(a) the licensed dealer is no longer eligible to apply for a licence under section 9; (b) the licensed dealer requests the Minister to do so or informs the Minister of the loss or theft of the licence or the actual or potential unauthorized use of the licence; (c) the licensed dealer ceases to conduct activities at their site before the expiry of their licence; (e) the licensed dealer has contravened (i) a provision of the Act, the Cannabis Act or their regulations, or (ii) a term or condition of a licence or permit issued to the dealer under a regulation made under the Act or issued to the dealer under the Cannabis Act or its regulations; (f) during the 10 years before the day on which the application is submitted, the senior person in charge, the qualified person in charge or any alternate qualified person in charge was convicted as specified in subparagraph 9.3(a)(ii) or (b)(ii) or received a sentence as specified in subparagraph 9.3(a)(ii) or (b)(ii); (g) the Minister has reasonable grounds to believe that the licensed dealer submitted false or misleading information or false or falsified documents in or in support of an application relating to the licence; or (h) information received from a competent authority or the United Nations gives the Minister reasonable grounds to believe that the licensed dealer has been involved in the diversion of a narcotic to an illicit market or use.
Les mesures que le ministre doit prendre avant d’envoyer un avis sont les suivantes : a) consulter l’autorité provinciale attributive de licences en matière d’activités professionnelles de la province où le pharmacien est autorisé à exercer; b) donner au pharmacien l’occasion de présenter ses observations à cet égard; c) prendre en considération les éléments suivants : (i) les antécédents du pharmacien quant au respect de la Loi et de ses règlements, (ii) la question de savoir si la conduite du pharmacien représente un risque d’atteinte à la sécurité ou à la santé publiques, notamment un risque de détournement du stupéfiant vers un marché ou un usage illicites. DORS/2003-134, art. 4; DORS/2010-221, art. 17 et 18(F); DORS/2013-119, art. 215; DORS/2016-230, art. 278; DORS/2018-147, art. 14; DORS/2019-169, art. 15. Avis de rétractation 49 Le ministre envoie à tous les destinataires d’un avis visé au paragraphe 48(1) un avis de rétractation de l’avis si les exigences ci-après sont respectées, selon le cas : a) dans le cas visé à l’alinéa 48(2)a), les conditions prévues aux sous-alinéas b)(i) et (ii) sont remplies et il s’est écoulé un an depuis l’envoi de l’avis par le ministre; b) dans les cas visés aux alinéas 48(2)b) et c) et 4)a) à f), le pharmacien nommé dans l’avis a satisfait aux exigences suivantes : (i) il lui a demandé par écrit d’envoyer un avis de rétractation de l’avis, (ii) il lui a fourni une lettre de l’autorité provinciale attributive de licences en matière d’activités professionnelles de la province où il est autorisé à exercer, Sections 49-54 SOR/2003-134, s. 4; SOR/2010-221, s. 17; SOR/2013-119, s. 216; SOR/2018-147, s. 15; SOR/2019-169, s. 16. 50 to 52 [Repealed, SOR/2003-134, s. 4] Practitioners Administer, Prescribe or Sell Narcotics [SOR/2019-169, s. 16] Conditions
The Minister must not revoke a dealer’s licence for a ground set out in paragraph (1)(e) or (g) if the licensed dealer meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a narcotic from being diverted to an illicit market or use: (a) the licensed dealer does not have a history of non-compliance with the Act, the Cannabis Act or their regulations; and (b) the licensed dealer has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their regulations.
Subject to subsection (4), a practitioner may administer a narcotic to a person or animal, or prescribe, sell or provide it for a person or animal, if
Before revoking a licence, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.
[Repealed, SOR/2018-37, s. 6] Heroin
[Repealed, SOR/2018-147, s. 16] SOR/85-930, s. 7; SOR/98-134, s. 6; SOR/2001-221, s. 71; SOR/2004-237, s. 20; SOR/2012-230, s. 22; SOR/2013-119, s. 217; SOR/2018-37, s. 6; SOR/2016-230, ss. 268, 278; SOR/2016-229, s. 8; SOR/2018-37, s. 6; SOR/2018-147, s. 16. Accessibility of record SOR/2004-237, s. 21; SOR/2013-119, s. 218; SOR/2016-230, s. 270; SOR/2018-147, s. 17; SOR/2019-169, s. 17. General Obligations of Practitioner [SOR/2019-169, s. 18] Requirements 55 A practitioner shall (iii) [Repealed, SOR/2018-147, s. 18] (d) permit an inspector to check all stocks of narcotics on the practitioner’s premises; SOR/2004-237, s. 22; SOR/2013-119, s. 219; SOR/2016-230, s. 271; SOR/2018-147, s. 18. 56 [Repealed, SOR/2010-221, s. 14] SOR/86-882, s. 2; SOR/2003-134, s. 5; SOR/2010-221, s. 17; SOR/2013-119, s. 220; SOR/2015-132, s. 2; SOR/2016-230, s. 272; SOR/2018-147, s. 19; SOR/2019-169, s. 19. (b) recipients of the notice must not sell or provide a verbal prescription narcotic to the practitioner; (d) pharmacists practising in the notified pharmacies must not fill a prescription or order for a verbal prescription narcotic from that practitioner. (e) [Repealed, SOR/2018-147, s. 20] (f) and (g) [Repealed, SOR/2013-119, s. 221] SOR/2003-134, s. 5; SOR/2013-119, s. 221; SOR/2016-230, s. 273; SOR/2018-147, s. 20. Circumstances requiring a notice Recipients Other circumstances c) soit que les interdictions prévues aux alinéas a) et b) s’appliquent concurremment relativement au praticien nommé dans l’avis. Cas exigeant l’avis
(a) their name, municipal address and dealer’s licence number; (b) with respect to the narcotic to be imported, (i) its name, as specified in the dealer’s licence, (ii) if it is a salt, the name of the salt, (iii) its quantity, and (iv) in the case of a raw material, its purity and its anhydrous content; (c) if the narcotic is contained in a product to be imported, (i) the brand name of the product, (ii) the drug identification number that has been assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any, and (iii) the strength per unit of the narcotic in the product, the number of units per package and the number of packages; (d) the name and municipal address of the exporter in the country of export from whom the narcotic is being obtained; (e) the name of the customs office where the importation is anticipated; and (f) each proposed mode of transportation and any proposed country of transit or transshipment. Signature and attestation
Les cas exigeant l’avis sont les suivants : a) le praticien nommé dans l’avis en fait la demande au ministre en vertu de l’article 58; b) il a contrevenu à une règle de conduite établie par l’autorité provinciale attributive de licences en matière d’activités professionnelles de la province où il exerce et l’autorité a demandé au ministre par écrit d’envoyer l’avis; c) il a été condamné pour une infraction désignée ou pour une contravention au présent règlement. Destinataires
The application must (a) be signed and dated by the qualified person in charge or an alternate qualified person in charge; and (b) include an attestation by that person that all of the information submitted in support of the application is correct and complete to the best of their knowledge. Additional information and documents
Les destinataires de l’avis sont les suivants : a) tous les distributeurs autorisés; b) les pharmacies de la province où le praticien nommé dans l’avis, d’une part, est inscrit et autorisé en vertu des lois de celle-ci à exercer sa profession et, d’autre part, l’y exerce; c) l’autorité provinciale attributive de licences en matière d’activités professionnelles de la province où le praticien nommé dans l’avis est inscrit et autorisé à exercer; d) les pharmacies d’une province adjacente qui pourraient exécuter une commande ou une ordonnance faites par le praticien nommé dans l’avis; e) l’autorité provinciale attributive de licences en matière d’activités professionnelles d’une autre province qui en a fait la demande par écrit au ministre. Autres cas
The licensed dealer must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.
Le ministre peut envoyer l’avis visé au paragraphe (1) au destinataire visé au paragraphe (3) s’il a pris les mesures prévues au paragraphe (5) et s’il a des motifs raisonnables de croire que le praticien nommé dans l’avis se trouve dans l’un des cas suivants : a) il a contrevenu à une disposition de la Loi ou du présent règlement; b) il s’est administré à plus d’une reprise un stupéfiant autre qu’un stupéfiant d’ordonnance verbale, obtenu sur commande ou ordonnance faites par lui ou, à Measures before sending notice SOR/2003-134, s. 5; SOR/2010-221, ss. 17, 18(F); SOR/2013-119, s. 222; SOR/2016-230, ss. 274, 278; SOR/2017-18, s. 25; SOR/2018-147, s. 21; SOR/2019-169, s. 20. Notice of retraction défaut de commande ou d’ordonnance, d’une façon non conforme aux pratiques professionnelles reconnues; c) il s’est administré à plus d’une reprise un stupéfiant d’ordonnance verbale, obtenu sur commande ou ordonnance faites par lui ou, à défaut de commande ou d’ordonnance, d’une façon non conforme aux pratiques professionnelles reconnues; d) il a, à plus d’une reprise, fait une ordonnance pour un stupéfiant autre qu’un stupéfiant d’ordonnance verbale, l’a fourni ou l’a administré à son époux ou conjoint de fait, à son père ou à sa mère ou son enfant, y compris un enfant adopté de fait, d’une façon non conforme aux pratiques professionnelles reconnues; e) il a, à plus d’une reprise, fait une ordonnance pour un stupéfiant d’ordonnance verbale, l’a fourni ou l’a administré à son époux ou conjoint de fait, à son père ou à sa mère ou son enfant, y compris un enfant adopté de fait, d’une façon non conforme aux pratiques professionnelles reconnues; f) il est dans l’impossibilité de rendre compte de la quantité d’un stupéfiant dont il avait la responsabilité en application du présent règlement. Mesures préalables
(c) the effective date of the permit; (i) a date specified by the Minister that is not more than 180 days after its effective date, and (e) any terms and conditions that the Minister has reasonable grounds to believe are necessary to (i) ensure that an international obligation is respected, or (ii) reduce a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use.
Les mesures que le ministre doit prendre avant d’envoyer un avis sont les suivantes : a) consulter l’autorité provinciale attributive de licences en matière d’activités professionnelles de la province où le praticien est inscrit et autorisé à exercer; b) donner au praticien l’occasion de présenter ses observations à cet égard; c) prendre en considération les éléments suivants : (i) les antécédents du praticien quant au respect de la Loi et de ses règlements, (ii) la question de savoir si la conduite du praticien représente un risque d’atteinte à la sécurité ou à la santé publiques, notamment un risque de détournement du stupéfiant vers un marché ou un usage illicite. DORS/2003-134, art. 5; DORS/2010-221, art. 17 et 18(F); DORS/2013-119, art. 222; DORS/2016-230, art. 274 et 278; DORS/2017-18, art. 25; DORS/2018-147, art. 21; DORS/2019-169, art. 20. Avis de rétractation 60 Le ministre envoie à tous les destinataires d’un avis visé au paragraphe 59(1) un avis de rétractation de l’avis SOR/88-588, s. 20; SOR/2003-134, s. 5; SOR/2010-221, s. 17; SOR/2013-119, s. 223; SOR/2018-147, s. 22; SOR/2019-169, s. 20. 61 and 62 [Repealed, SOR/2003-134, s. 5] Hospitals General obligations (vi) the name of the practitioner ordering or prescribing a narcotic, other than dextropropoxyphene or a verbal prescription narcotic, and d’interdiction si les exigences ci-après sont respectées, selon le cas : a) dans le cas visé à l’alinéa 59(2)a), les conditions prévues aux sous-alinéas b)(i) et (ii) sont remplies et il s’est écoulé un an depuis l’envoi de l’avis d’interdiction; b) dans les cas visés aux alinéas 59(2)b) et c) et 4(a) à f), le praticien nommé dans l’avis satisfait aux exigences suivantes : (i) il lui a demandé par écrit d’envoyer un avis de rétractation de l’avis, (ii) il lui a fourni une lettre de l’autorité provinciale attributive de licences en matière d’activités professionnelles de la province où il est inscrit et autorisé à exercer, dans laquelle l’autorité accepte la rétractation de l’avis d’interdiction. DORS/88-588, art. 20; DORS/2003-134, art. 5; DORS/2010-221, art. 17; DORS/2013-119, art. 223; DORS/2018-147, art. 22; DORS/2019-169, art. 20. 61 et 62 [Abrogés, DORS/2003-134, art. 5] Hôpitaux Obligations générales 63 Le responsable d’un hôpital satisfait aux exigences suivantes : a) tenir ou faire tenir un cahier, un registre ou autre dossier réservé à cette fin, (i) du nom et de la quantité de tout stupéfiant qui a été reçu, (ii) du nom et de l’adresse de la personne de qui tout stupéfiant a été reçu ainsi que de la date de réception, (iii) du nom et de la quantité de tout stupéfiant utilisé dans la fabrication ou l’assemblage d’un produit ou d’un composé qui contient ce stupéfiant, (iv) du nom et de la quantité de tout produit ou composé fabriqué ou assemblé qui contient ce stupéfiant ainsi que de la date de fabrication ou d’assemblage, (v) du nom du malade pour lequel a été dispensé un stupéfiant autre qu’un stupéfiant d’ordonnance verbale ou que du dextropropoxyphène, (vi) du nom du praticien qui commande ou prescrit un stupéfiant autre qu’un stupéfiant d’ordonnance verbale ou que du dextropropoxyphène, et (viii) to (x) [Repealed, SOR/2018-147, s. 23] SOR/82-1073, s. 2; DORS/85-588, s. 21(E); SOR/2004-237, s. 24; SOR/2013-119, s. 224; SOR/2016-230, s. 275; SOR/2018-147, s. 23; SOR/2019-169, s. 21(F). d) permit an inspector to check all stocks of narcotics in the hospital. SOR/2019-169, s. 22(F). Written order or prescription (vii) de la date où un stupéfiant autre qu’un stupéfiant d’ordonnance verbale ou que du dextropropoxyphène est commandé ou prescrit, ainsi que la forme et la quantité en cause; (viii) à (x) [Abrogés, DORS/2018-147, art. 23] b) conserver les renseignements consignés dans une forme qui permette de faire une vérification de temps à autre durant une période d’au moins deux ans à compter de la date où les renseignements ont été consignés; c) prendre toutes les mesures nécessaires pour protéger les stupéfiants dans l’hôpital contre la perte et le vol, et signaler au ministre toute perte ou vol de stupéfiant, 10 jours au plus après en avoir fait la découverte. DORS/82-1073, art. 2; DORS/85-588, art. 21(A); DORS/2004-237, art. 24; DORS/2013-119, art. 224; DORS/2016-230, art. 275; DORS/2018-147, art. 23; DORS/2019-169, art. 21(F). Fourniture de renseignements et assistance à l’inspecteur 64 Le responsable d’un hôpital satisfait aux exigences suivantes : a) fournir tout renseignement relatif à l’emploi des stupéfiants dans l’hôpital, dans la forme et au moment que peut fixer le ministre; b) présenter à un inspecteur tous les cahiers, dossiers, registres ou documents que le présent règlement exige de tenir; c) permettre à un inspecteur de prendre copie ou de noter des extraits desdits cahiers, registres ou documents; et d) permettre à un inspecteur de vérifier tous les stocks de stupéfiants dans l’hôpital. DORS/2019-169, art. 22(F). Administration, vente et fourniture de stupéfiants 65 (1) Il est interdit au responsable d’un hôpital de permettre qu’un stupéfiant soit administré, vendu ou fourni si ce n’est en conformité avec le présent article. Commande ou ordonnance écrites
(b) the date of the suspension or revocation of the permit under section 19 or 20, (c) the date of the suspension or revocation of the dealer’s licence under section 16 or 17, and (d) the date of the suspension or revocation of the export permit that applies to the narcotic to be imported and that is issued by the competent authority in the country of export.
Le responsable d’un hôpital peut, à la réception d’une commande ou d’une ordonnance écrites, signées et datées par un praticien, permettre qu’un stupéfiant, autre que la diacétylmorphine (héroïne), soit administré à une personne ou à un animal qui reçoit un traitement comme patient hospitalisé ou externe de l’hôpital ou soit vendu ou fourni pour cette dernière ou au responsable de l’animal. Verbal prescription narcotic (3.1) [Repealed, SOR/2018-147, s. 24] Emergency — pharmacist
[Repealed, SOR/2018-37, s. 7] Signature (5.2) [Repealed, SOR/2018-147, s. 24] Heroin Hospitals Sections 65-68 SOR/85-588, s. 22; SOR/85-930, s. 8; SOR/88-279, s. 2(F); SOR/91-124, s. 7; SOR/ 2004-237, s. 25; SOR/2012-230, s. 23; SOR/2013-119, s. 25; SOR/2013-172, s. 8; SOR/ 2014-51, s. 2; SOR/2016-239, s. 16; SOR/2018-37, s. 7; SOR/2018-147, s. 24; SOR/2019-165, s. 23.
(a) the licensed dealer is not authorized by their dealer’s licence to import the relevant narcotic or their licence will expire before the date of importation; (b) the Minister has reasonable grounds to believe that the importation would contravene an international obligation; (c) the licensed dealer does not have in place at the site the security measures set out in the Security Directive in respect of the importation; (d) the licensed dealer has not complied with the requirements of subsection 18(3) or the information or documents that they have provided are not sufficient to complete the review of the permit application; (e) the Minister has reasonable grounds to believe that the licensed dealer has submitted false or misleading information or false or falsified documents in or in support of the permit application; (f) the licensed dealer has been notified that their application to renew or amend their licence will be refused; (g) the Minister has reasonable grounds to believe that the importation would contravene the laws of the country of export or any country of transit or transhipment; or (h) the Minister has reasonable grounds to believe that the issuance of the permit would likely create a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use.
Before refusing to issue the import permit, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.
66 [Repealed, SOR/97-227, s. 3] Opium poppy SOR/2013-119, s. 27(E); SOR/2016-123, s. 2(F); SOR/2018-147, s. 26. (a) a practitioner of medicine; or Agent or mandatary of practitioner of medicine (a) the practitioner; or (b) the Minister. Practitioner of medicine (b) to the Minister. Règlement sur les stupéfiants Hôpitaux
(a) their name and the numbers of their dealer’s licence and the import permit that applies to the narcotic; (b) with respect to the narcotic, (i) its name, as set out in the dealer’s licence, (ii) if it is a salt, the name of the salt, and (iii) its quantity; (c) if the narcotic is contained in a product that they have imported, (i) the brand name of the product, (ii) the drug identification number that has been assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any, and (iii) the strength per unit of the narcotic in the product, the number of units per package and the number of packages; and (d) the name of the customs office from which the narcotic was released and the date of the release.
des traitements comme patient hospitalisé ou externe de l’hôpital. DORS/85-588, art. 22; DORS/85-930, art. 8; DORS/88-279, art. 2(F); DORS/91-124, art. 7; DORS/2004-237, art. 25; DORS/2012-230, art. 23; DORS/2013-119, art. 25; DORS/ 2013-172, art. 8; DORS/2014-51, art. 2; DORS/2016-239, art. 16; DORS/2018-37, art. 7; DORS/2018-147, art. 24; DORS/2019-165, art. 23.
(a) the dealer’s licence is suspended; (b) the Minister has reasonable grounds to believe that the suspension is necessary to protect public health or safety, including to prevent a narcotic from being diverted to an illicit market or use; or (c) the importation would contravene the laws of the country of export or any country of transit or transhipment.
The suspension takes effect as soon as the Minister sends the licensed dealer a notice that (a) sets out the reasons for the suspension; (b) gives the dealer an opportunity to be heard; and (c) if applicable, specifies the corrective measures that must be carried out and the date by which they must be carried out.
The Minister must reinstate the import permit if the Minister has reasonable grounds to believe that the suspension is no longer necessary. Revocation
Dispositions générales 66 [Abrogé, DORS/97-227, art. 3] Pavot à opium 67 Le ministre peut, suivant une demande à cet effet, délivrer une licence à toute personne qui, de l’avis du ministre, a qualité pour produire le pavot à opium à des fins scientifiques, aux conditions que le ministre juge nécessaires. DORS/2013-119, art. 27(A); DORS/2016-123, art. 2(F); DORS/2018-147, art. 26. Identification ou analyse de stupéfiants 68 (1) Toute personne peut, malgré toute disposition du présent règlement, fournir ou livrer un stupéfiant à des fins d’identification ou d’analyse aux personnes suivantes : a) le médecin; b) le mandataire d’un médecin, si le mandataire bénéficie d’une exemption relative à la possession de ce stupéfiant à ces fins et accordée en vertu de l’article 56 de la Loi. Mandataire d’un médecin
(a) the licensed dealer requests the Minister to do so or informs the Minister of the loss or theft of the permit or the actual or potential unauthorized use of the permit; (b) the licensed dealer does not carry out the corrective measures specified by the Minister under paragraph 19(2)(c) by the specified date; (c) the licensed dealer has contravened a term or condition of the permit; (d) the Minister has reasonable grounds to believe that the licensed dealer submitted false or misleading information or false or falsified documents in or in support of the application for the permit; (e) information received from a competent authority or the United Nations gives the Minister reasonable grounds to believe that the licensed dealer has been involved in the diversion of a narcotic to an illicit market or use; or (f) the dealer’s licence has been revoked.
Le mandataire d’un médecin qui reçoit le stupéfiant le fournit ou le livre immédiatement à l’une des personnes suivantes : a) le médecin; b) le ministre. Médecin
The Minister must not revoke an import permit for a ground set out in paragraph (1)(d) or 17(1)(e) or (g) if the licensed dealer meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a narcotic from being diverted to an illicit market or use: (a) the licensed dealer does not have a history of non-compliance with the Act, the Cannabis Act or their regulations; and (b) the licensed dealer has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their regulations.
Le médecin qui reçoit le stupéfiant le fournit ou le livre immédiatement à l’une des personnes suivantes : a) la personne qui bénéficie d’une exemption relative à la possession de ce stupéfiant à ces fins et accordée en vertu de l’article 56 de la Loi si le stupéfiant est fourni ou livré à des fins d’identification ou d’analyse; b) le ministre. (a) advertise a narcotic to the general public; 71 [Repealed, SOR/2019-169, s. 25] Content of notice
Before revoking an import permit, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.
The notification must specify SOR/97-227, s. 4; SOR/2019-169, s. 26. Definitions SOR/82-121, s. 1; SOR/2010-221, s. 24; SOR/2012-230, s. 24; SOR/2013-119, s. 228; SOR/2016-230, s. 278; SOR/2018-147, s. 27; SOR/2019-169, s. 27. SOR/97-227, s. 5; SOR/2019-169, s. 27. l’une de ses activités, est soustrait à l’application du paragraphe 4(2) ou des articles 5, 6, ou 7 de la Loi en vertu du Règlement sur l’exécution policière de la Loi réglementant certaines drogues et autres substances est, à l’égard de cette activité, soustrait à l’application du présent règlement. DORS/97-227, art. 5; DORS/2019-169, art. 27. SCHEDULE (Section 2)
Opium
(a) their name, municipal address and dealer’s licence number; (b) with respect to the narcotic to be exported, (i) its name, as specified in the dealer’s licence, Narcotic Control Regulations Licensed Dealers (ii) if it is a salt, the name of the salt, (iii) its quantity, and (iv) in the case of a raw material, its purity and its anhydrous content; (c) in the case of the exportation of a product that contains the narcotic, (i) the brand name of the product, (ii) the drug identification number that has been assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any, and (iii) the strength per unit of the narcotic in the product, the number of units per package and the number of packages; (e) the name of the customs office where the exportation is anticipated; (f) each proposed mode of transportation to be used and any proposed country of transit or transhipment; and (g) a copy of the import permit issued by the competent authority in the country of final destination that sets out the name of the importer and the municipal address of their site in that country. Signature and attestation
Codeine (methylmorphine)
The application must (a) be signed and dated by the qualified person in charge or an alternate qualified person in charge; and (b) include an attestation by that person that, to the best of their knowledge, (i) the exportation does not contravene any requirement of the laws of the country of final destination or any country of transit or transhipment, and (ii) all of the information and documents submitted in support of the application are correct and complete. Additional information and documents
Morphine (7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol)
The licensed dealer must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.
Thebaine (paramorphine)
(c) the effective date of the permit; (i) a date specified by the Minister that is not more than 180 days after its effective date, (iii) the expiry date of the import permit issued by the competent authority in the country of final destination; and (e) any terms and conditions that the Minister has reasonable grounds to believe are necessary to (i) ensure that an international obligation is respected, or (ii) reduce a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use.
Acetorphine (acetylethorphine)
(b) the date of the suspension or revocation of the permit under section 22 or 23, (c) the date of the suspension or revocation of the dealer’s licence under section 16 or 17, and Narcotic Control Regulations Licensed Dealers (d) the date of the expiry, suspension or revocation of the import permit that applies to the narcotic to be exported and that is issued by the competent authority in the country of final destination.
Acetyldihydrocodeine (4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol acetate)
Benzylmorphine (7,8-didehydro-4,5-epoxy-17-methyl-3-(phenylmethoxy)morphinan-6-ol)
(a) the licensed dealer is not authorized by their dealer’s licence to export the relevant narcotic or their dealer’s licence will expire before the date of export; (b) the Minister has reasonable grounds to believe that the exportation would contravene an international obligation; (c) the licensed dealer has not complied with the requirements of subsection 21(3) or the information or documents that they have provided are not sufficient to complete the review of the permit application; (d) the Minister has reasonable grounds to believe that the licensed dealer has submitted false or misleading information or false or falsified documents in or in support of the permit application; (e) the licensed dealer has been notified that their application to renew or amend their licence will be refused; (f) the Minister has reasonable grounds to believe that the exportation would not be in conformity with the import permit issued by the competent authority of the country of final destination; (g) the Minister has reasonable grounds to believe that the exportation would contravene the laws of the country of final destination or any country of transit or transshipment; or (h) the Minister has reasonable grounds to believe that the issuance of the permit would likely create a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use. Narcotic Control Regulations Licensed Dealers
Codoxime (dihydrocodeinone O-(carboxymethyl)oxime)
Before refusing to issue the export permit, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.
Desomorphine (dihydrodesoxymorphine)
Diacetylmorphine (heroin)
(a) their name and the numbers of their dealer’s licence and the export permit that applies to the narcotic; (b) with respect to the narcotic, (i) its name, as specified in the dealer’s licence, (ii) if it is a salt, the name of the salt, and (iii) its quantity; (c) if the narcotic is contained in a product that they have exported, (i) the brand name of the product, (ii) the drug identification number that has been assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any, and (iii) the strength per unit of the narcotic in the product, the number of units per package and the number of packages; and (d) the name of the customs office from which the narcotic was exported and the date of export.
Dihydrocodeine (4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol)
(a) the dealer’s licence is suspended; (b) the Minister has reasonable grounds to believe that the suspension is necessary to protect public health or safety, including to prevent a narcotic from being diverted to an illicit market or use; or (c) the exportation would contravene the laws of the country of final destination or any country of transit or transshipment.
Dihydromorphine (4,5-epoxy-17-methylmorphinan-3,6-diol)
The suspension takes effect as soon as the Minister sends the licensed dealer a notice that (a) sets out the reasons for the suspension; (b) gives the dealer an opportunity to be heard; and (c) if applicable, specifies the corrective measures that must be carried out by the dealer and the date by which the dealer must do so.
Ethylmorphine (7,8-didehydro-4,5-epoxy-3-ethoxy-17-methylmorphinan-6-ol)
The Minister must reinstate the export permit if the Minister has reasonable grounds to believe that the suspension is no longer necessary. Revocation
Etorphine (tetrahydro-7α-(1-hydroxy-1-methylbutyl)-6,14-endo-ethenooripavine)
(a) the licensed dealer requests the Minister to do so or informs the Minister of the loss or theft of the permit or the actual or potential unauthorized use of the permit; (b) the licensed dealer does not carry out the corrective measures specified by the Minister under paragraph 22(2)(c) by the specified date; (c) the licensed dealer has contravened a term or condition of the permit; (d) the Minister has reasonable grounds to believe that the licensed dealer submitted false or misleading information or false or falsified documents in or in support of the application for the permit; (e) information received from a competent authority or the United Nations gives the Minister reasonable grounds to believe that the licensed dealer has been involved in the diversion of a narcotic to an illicit market or use; or (f) the dealer’s licence has been revoked.
Hydrocodone (dihydrocodeinone)
The Minister must not revoke an export permit for a ground set out in paragraph (1)(d) or 17(1)(e) or (g) if the licensed dealer meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a narcotic from being diverted to an illicit market or use: (a) the licensed dealer does not have a history of non-compliance with the Act, the Cannabis Act or their regulations; and (b) the licensed dealer has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act or their regulations.
Hydromorphinol (dihydro-14-hydroxymorphine)
Before revoking an export permit, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.
Hydromorphone (dihydromorphinone)
Identification
Methyldesorphine (Δ6-deoxy-6-methylmorphine)
Sale to another licensed dealer
Methyldihydromorphine (dihydro-6-methylmorphine)
Metopon (dihydromethylmorphinone)
Exception — pharmacist named in notice
Morphine-N-oxide (morphine oxide)
A licensed dealer must not sell or provide to a pharmacist who is named in a notice issued under subsection 48(1) the narcotics referred to in the notice.
Myrophine (benzylmorphine myristate) --- ANNEXE (article 2) 1 Pavot à opium (*Papaver somniferum*), ainsi que ses préparations, dérivés, alcaloïdes et sels, notamment :
Subsection (2) does not apply to a licensed dealer that has received a notice of retraction issued under section 49 in respect of a pharmacist named in a notice issued under subsection 48(1).
opium
codéine (méthylmorphine)
A licensed dealer may sell or provide diacetylmorphine (heroin) to the following practitioners: (b) a practitioner of dentistry, if practising in a hospital that provides care or treatment to persons; or (c) a nurse practitioner. Exception — practitioner named in notice
morphine (didéhydro-7,8 époxy-4,5 méthyl-17 morphinanediol-3,6)
A licensed dealer must not sell or provide to a practitioner who is named in a notice issued under subsection 59(1) the narcotics referred to in the notice unless the dealer has received a notice of retraction issued under section 60.
thébaïne (paramorphine) les sels, les dérivés et les sels des dérivés des substances visées aux paragraphes (1) à (4), notamment :
acétorphine (acétyléthorphine)
A licensed dealer may provide diacetylmorphine (heroin) to a hospital employee only if that hospital provides care or treatment to persons.
acétyldihydrocodéine (époxy-4,5 acétoxy-6 méthoxy-3 méthyl-17 morphinane)
Sale to Minister
benzylmorphine (didéhydro-7,8 époxy-4,5 hydroxy-6 méthyl-17 (phénylméthoxy)-3 morphinane)
Written order
codoxime (O-(carboxyméthyl) oxime de dihydrocodéinone)
(a) the dealer has received a written order that specifies the name and quantity of the narcotic to be supplied and is signed and dated (i) in the case of a narcotic to be provided to a hospital employee or a practitioner in a hospital, by the pharmacist in charge of the hospital’s pharmacy or by a practitioner authorized by the person in charge of the hospital to sign the order, and (ii) in any other case, by the person to whom the narcotic is to be sold or provided; and (b) the dealer has verified the signature, if it is unknown to them.
désomorphine (dihydrodesoxymorphine)
(a) the dealer has received a verbal order that specifies the name and quantity of the narcotic to be supplied; and (b) in the case of the provision of the narcotic to a hospital employee or a practitioner in a hospital, the order has been placed by the pharmacist in charge of the hospital’s pharmacy or by a practitioner authorized by the person in charge of the hospital to place the order.
diacétylmorphine (héroïne)
A licensed dealer that receives a verbal order from a pharmacist or practitioner must, within five working days after filling the order, obtain and keep a receipt that includes (a) the signature of the pharmacist or practitioner who received the narcotic; (b) the date on which the pharmacist or practitioner received the narcotic; and (c) the name and quantity of the narcotic. No further sale without receipt
dihydrocodéine (époxy-4,5 hydroxy-6 méthoxy-3 méthyl-17 morphinane)
If the licensed dealer has not obtained the receipt within five working days, the dealer must not sell or provide a narcotic to the pharmacist or practitioner in accordance with a further verbal order received from them until after obtaining the receipt. Packaging and Transportation Packaging — sale and provision
dihydromorphine (époxy-4,5 méthyl-17 morphinandiol-3,6)
Packaging — transport and export
éthylmorphine (didéhydro-7,8 époxy-4,5 éthoxy-3 méthyl-17 morphinane)
A licensed dealer that transports or exports a narcotic must ensure that its package is sealed in such a manner that the package cannot be opened without breaking the seal.
étorphine (((hydroxy-1 méthyl-1 butyl)-7α endoéthéno-6,14 tétrahydro-oripavine))
Subsection (1) does not apply to a test kit that contains a narcotic and that has a registration number. Transport
hydrocodone (dihydrocodéinone)
(a) take any measures that are necessary to ensure the security of the narcotic while it is being transported; (b) subject to subsection (2), use a method of transportation that permits an accurate record to be kept of all handling of the narcotic as well as of the signatures of every person handling the narcotic until it is delivered to the consignee; (c) in the case of an imported narcotic, transport it directly to the site specified in their licence after it is released under the Customs Act; and (d) in the case of a narcotic that is to be exported, transport it directly from the site specified in their licence to the customs office where it will be exported.
hydromorphinol (hydroxy-14 dihydromorphine)
A licensed dealer may have a verbal prescription narcotic transported by a common carrier. Thefts, Losses and Suspicious Transactions Protective measures
hydromorphone (dihydromorphinone)
méthyldésorphine (méthyl-6 delta-6 désoxymorphine)
méthyldihydromorphine (méthyl-6 dihydromorphine)
(a) provide a written report to a member of a police force within 24 hours after becoming aware of the theft or loss; and (b) provide a written report to the Minister within 72 hours after becoming aware of the theft or loss and confirm that the report referred to in paragraph (a) has been made. (b) provide a written report to the Minister within 72 hours after becoming aware of the theft or loss and include a confirmation that the report required under paragraph (a) has been provided.
métopon (méthyl-5 dihydromorphinone)
(a) their name, municipal address, telephone number and, if the licensed dealer is a corporation, the position held by the individual making the report; (b) the name and municipal address of the other party to the transaction; (c) details of the transaction, including its date and time, its type, the name and quantity of the narcotic and, in the case of a product or compound, the quantity of every narcotic it contains; (d) in the case of a product that contains the narcotic, other than a test kit, the drug identification number that is assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any; (e) a detailed description of the reasons for those suspicions.
N-oxymorphine (oxyde de morphine)
No civil proceedings lie against a licensed dealer for having provided the report in good faith. Non-disclosure
Nalorphine (N-allylnormorphine)
A licensed dealer must not disclose that they have provided the report or disclose details of it, with the intent to prejudice a criminal investigation, whether or not a criminal investigation has begun. Partial protection against self-incrimination
Nicocodeine (6-nicotinylcodeine)
Destruction at site
Nicomorphine (dinicotinylmorphine)
(a) the licensed dealer obtains the prior approval of the Minister; (b) the destruction is carried out in the presence of two of the following persons, at least one of whom must be a person referred to in subparagraph (i): (i) the senior person in charge, the qualified person in charge or an alternate qualified person in charge, and (ii) a person who works for or provides services to the licensed dealer and holds a senior position; (c) the destruction is carried out in accordance with a method that complies with all federal, provincial and municipal environmental protection legislation applicable to the place of destruction; and (d) as soon as the destruction is complete, the person who carried out the destruction and each of the two persons referred to in paragraph (b) who were present at the destruction sign and date a joint declaration attesting that the narcotic was completely destroyed, to which each signatory must add their name in printed letters. Destruction elsewhere than at site
Norcodeine (N-desmethylcodeine)
(a) the licensed dealer obtains the prior approval of the Minister; (b) the licensed dealer takes any measures that are necessary to ensure the security of the narcotic while it is being transported in order to prevent its diversion to an illicit market or use; (c) the destruction is carried out by a person working for a business that specializes in the destruction of Narcotic Control Regulations Licensed Dealers dangerous goods and in the presence of another person working for that business; (d) the destruction is carried out in accordance with a method that complies with all federal, provincial and municipal environmental protection legislation applicable to the place of destruction; and (e) as soon as the destruction is completed, the person who carried out the destruction provides the licensed dealer with a dated declaration attesting that the narcotic was completely destroyed and containing (i) the municipal address of the place of destruction, (ii) the name and quantity of the narcotic and, if applicable, the brand name and quantity of the product containing it or the name and quantity of the compound containing it, (iii) the method of destruction, (iv) the date of destruction, and (v) the names in printed letters and signatures of that person and the other person who was present at the destruction. Application for prior approval
Normorphine (N-desmethylmorphine)
(a) their name, municipal address and dealer’s licence number; (b) the proposed date of destruction; (c) the municipal address of the place of destruction; (e) if the destruction is to be carried out at the site specified in the dealer’s licence, the names of the persons proposed for the purpose of paragraph 27.5(b) and information establishing that they meet the conditions of that paragraph; (f) the name of the narcotic and, if applicable, the brand name of the product containing it or the name of the compound containing it; and (g) the form and quantity of the narcotic or the product or compound containing it and, if applicable, the strength per unit of the narcotic in the product or compound, the number of units per package and the number of packages. Signature and attestation
Oxycodone (dihydrohydroxycodeinone)
The application must (a) be signed and dated by the qualified person in charge or an alternate qualified person in charge; and (b) include an attestation by that person that (i) the proposed method of destruction complies with all federal, provincial and municipal environmental protection legislation applicable to the place of destruction, and (ii) all of the information submitted in support of the application is correct and complete to the best of the signatory’s knowledge. Additional information and documents
Oxymorphone (dihydrohydroxymorphinone)
The licensed dealer must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.
Pholcodine (3-[2-(4-morpholinyl)ethyl]morphine)
(a) in the case of a destruction that is to be carried out at the site specified in the dealer’s licence, the persons proposed for the purpose of paragraph 27.5(b) do not meet the conditions of that paragraph; (b) the Minister has reasonable grounds to believe that the narcotic would not be destroyed; (c) the Minister has reasonable grounds to believe that the licensed dealer has submitted false or misleading information or false or falsified documents in or in support of the approval application; or a preliminary inquiry, trial or other proceeding under any Act or its regulations; or (e) the Minister has reasonable grounds to believe that the approval would likely create a risk to public health or safety, including the risk of the narcotic being diverted to an illicit market or use. Method of recording information
Thebacone (acetyldihydrocodeinone)
Apomorphine (5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol) and its salts
(a) the name, form and quantity of any narcotic that the dealer orders, the name of the person who places the order on the dealer’s behalf and the date of the order; (b) the name, form and quantity of any narcotic that the dealer receives, the name and municipal address of the person who sold or provided it and the date on which it was received; (c) in the case of a narcotic that the dealer sells or provides, (i) the brand name of the product or the name of the compound containing the narcotic and the name of the narcotic, (ii) the drug identification number that has been assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any, (iii) the form and quantity of the narcotic and, if applicable, the strength per unit of the narcotic in the product or compound, the number of units per package and the number of packages, (iv) the name and municipal address of the person to whom it was sold or provided, and (v) the date on which it was sold or provided; (d) the name, form and quantity of any narcotic that the dealer manufactures or assembles and the date on which it was placed in stock and, if applicable, the strength per unit of the narcotic in the product or compound, the number of units per package and the number of packages; (e) the name and quantity of any narcotic that the dealer uses in the manufacturing or assembling of a product or compound, as well as the brand name and quantity of the product or the name and quantity of the compound, and the date on which the product or compound was placed in stock; (f) the name, form and quantity of any narcotic in stock at the end of each month; (g) the name, form and quantity of any narcotic that the dealer delivers, transports or sends, the name and municipal address of the consignee and the date on which it was delivered, transported or sent; (h) the name, form and quantity of any narcotic that the dealer imports, the date on which it was imported, the name and municipal address of the exporter, the country of exportation and any country of transit or transhipment; and (i) the name, form and quantity of any narcotic that the dealer exports, the date on which it was exported, the name and municipal address of the importer, the country of final destination and any country of transit or transhipment.
Cyprenorphine (N-(cyclopropylmethyl)-6,7,8,14-tetrahydro-7α-(1-hydroxy-1-methylethyl)-6,14-endo-ethenoenorphinanone) and its salts (33.1) [Repealed, SOR/2016-239, s. 8]
(a) the name of the person who placed the order; (b) the date on which the order was received; and (c) the name of the person recording the order.
Nalmefene (17-(cyclopropylmethyl)-4,5α-epoxy-6-methylenemorphinan-3,14-diol) and its salts (34.1) Naloxone (4,5α-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one) and its salts (34.2) Naltrexone (17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one) and its salts (34.3) Methylnaltrexone (17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium) and its salts (34.4) Naloxegol (4,5α-epoxy-6α-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propenyl)morphinan-3,14-diol) and its salts
(a) the name of the lost narcotic and, if applicable, the brand name of the product or the name of the compound containing it; (b) the form and quantity of the narcotic and, if applicable, the form and quantity of the product or compound containing it, the strength per unit of the narcotic in the product or compound, the number of units per package and the number of packages; (c) the date on which the dealer became aware of the loss; and
Poppy seed
(b) the name, form and quantity of the narcotic and, if applicable, the brand name and quantity of the product containing the narcotic or the name and quantity of the compound containing the narcotic; (c) the method of destruction; and Annual report
Coca leaves
(a) the name, form and total quantity of each narcotic that they receive, produce, sell, provide, import, export or destroy during the calendar year, as well as the name and total quantity of each narcotic that they use to manufacture or assemble a product or compound; (b) the name, form and quantity of each narcotic in physical inventory taken at the site specified in their licence at the end of the calendar year; and (c) the name, form and quantity of any narcotic that has been lost or stolen in the course of conducting activities during the calendar year. Non-renewal or revocation within first three months
Cocaine (benzoylmethylecgonine)
If a licensed dealer’s licence expires without being renewed or is revoked during the first three months of a calendar year, the dealer must provide to the Minister (a) within three months after the end of the preceding calendar year, the annual report in respect of that year; and (b) within three months after the expiry or revocation, a report in respect of the portion of the current calendar year during which the licence was valid that contains the information referred to in subsection (1), in which the quantity in physical inventory is to be calculated as of the date of expiry or revocation. Non-renewal or revocation after third month
Ecgonine (3-hydroxy-2-tropane carboxylic acid)
If a licensed dealer’s licence expires without being renewed or is revoked after the first three months of a calendar year, the dealer must provide to the Minister, within three months after the expiry or revocation, a report in respect of the portion of the calendar year during which the licence was valid that contains the information referred to in subsection (1) for that period, in which the quantity in physical inventory is to be calculated as of the date of expiry or revocation.
¹²³I-ioflupane
Location
Allylprodine (3-allyl-1-methyl-4-phenyl-4-piperidinol propionate)
(a) in the case of a licensed dealer, at the site specified in their licence; and (b) in the case of a former licensed dealer, at a location in Canada. Narcotic Control Regulations Licensed Dealers Quality of documents
Alphameprodine (α-3-ethyl-1-methyl-4-phenyl-4-piperidinol propionate)
Pharmacists Record of Narcotics Received
Alphaprodine (α-1,3-dimethyl-4-phenyl-4-piperidinol propionate)
(a) the name and quantity of the narcotic received; (b) the date the narcotic was received; and (c) the name and address of the person from whom the narcotic was received. Restriction
Anileridine (ethyl 1-[2-(p-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate)
Exemption or written order or prescription
Betaprodine (ß-1,3-dimethyl-4-phenyl-4-piperidinol propionate)
A pharmacist may sell or provide a narcotic to a person (a) if the person is exempted under section 56 of the Act with respect to the possession of that narcotic; (b) except in the case of diacetylmorphine (heroin), if the pharmacist has received a written order or prescription for the narcotic that is signed and dated by a practitioner and has verified the signature of the practitioner, if it is not known to them; or (c) in the case of diacetylmorphine (heroin), if the pharmacist has received a written order or prescription for the narcotic that is signed and dated by a practitioner of medicine or a nurse practitioner and has verified the signature of the practitioner, if it is not known to them. Restriction Narcotic Control Regulations Pharmacists Sections 31-32
Benzethidine (ethyl 1-(2-benzyloxyethyl)-4-phenylpiperidine-4-carboxylate)
A pharmacist may sell or provide methadone to the following persons, in addition to the persons referred to in subsection (2): (a) a licensed dealer; (b) another pharmacist; (c) a hospital employee; or Prohibition — pharmacist or practitioner named in notice
Diphenoxylate (ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate)
(a) sell or provide a narcotic, other than a verbal prescription narcotic, to a pharmacist named in a notice issued by the Minister under paragraph 48(1)(a); (b) sell or provide a verbal prescription narcotic, other than a preparation mentioned in section 36, to a pharmacist named in a notice issued by the Minister under paragraph 48(1)(b); (c) sell or provide a preparation mentioned in section 36 to a pharmacist named in a notice issued by the Minister under paragraph 48(1)(c); (d) dispense, sell or provide a narcotic, other than a verbal prescription narcotic, to a practitioner named in a notice issued by the Minister under subsection 59(1) or fill a prescription or order for a narcotic, other than a verbal prescription narcotic, from a practitioner named in such a notice; or (e) dispense, sell or provide a verbal prescription narcotic to a practitioner named in a notice issued by the Minister under subsection 59(1) or fill a prescription or order for a verbal prescription narcotic from a practitioner named in such a notice. Articles 31-32
Difenoxin (1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate)
(a) under section 49, in respect of a pharmacist named in a notice issued by the Minister under subsection 48(1); or (b) under section 60, in respect of a practitioner named in a notice issued by the Minister to under subsection 59(1).
Etoxeridine (ethyl 1-[2-(2-hydroxyethoxy)ethyl]-4-phenylpiperidine-4-carboxylate)
Furethidine (ethyl 1-(2-tetrahydrofurfuroxyethyl)-4-phenylpiperidine-4-carboxylate)
(b) except in the case of diacetylmorphine (heroin), a practitioner who is authorized by the person in charge of the hospital to sign the order; or (c) in the case of diacetylmorphine (heroin), a practitioner of medicine or dentistry or a nurse practitioner who is authorized by the person in charge of the hospital to sign the order.
Hydroxypethidine (ethyl 4-(m-hydroxyphenyl)-1-methylpiperidine-4-carboxylate) Ketobemidone (1-[4-(m-hydroxyphenyl)-1-methyl-4-piperidyl]-1-propanone) Morpheridine (ethyl 1-(2-morpholinoethyl)-4-phenylpiperidine-4-carboxylate) Norpethidine (ethyl 4-phenylpiperidine-4-carboxylate) Pethidine (ethyl 1-methyl-4-phenylpiperidine-4-carboxylate) Phenoperidine (ethyl 1-[3-hydroxy-3-phenylpropyl]-4-phenylpiperidine-4-carboxylate) Piminodine (ethyl 1-[3-(phenylamino)propyl]-4-phenylpiperidine-4-carboxylate)
Before providing a narcotic under subsection (1), the pharmacist receiving the order must know the signature on the order or verify it.
Dimethylaminodiphenylbutanonitrile (4-cyano-2-dimethylamino-4,4-diphenylbutane)
(a) the preparation contains (i) two additional medicinal ingredients other than a narcotic in a quantity of not less than the regular minimum single dose for one such ingredient or one-half the regular minimum single dose for each such ingredient, and (ii) three additional medicinal ingredients other than a narcotic in a quantity of not less than the regular minimum single dose for one such ingredient or one-third the regular minimum single dose for each such ingredient; and (b) there is legibly and conspicuously printed on the inner label and the outer label, as those terms are defined in section A.01.010 of the Food and Drug Regulations, a caution to the following effect: “This preparation contains codeine and should not be administered to children except on the advice of a physician, dentist or nurse practitioner.” Use other than for recognized medical or dental purpose
Dipipanone (4,4-diphenyl-6-piperidino-3-heptanone)
No pharmacist shall sell or provide a preparation referred to in subsection (1) if the pharmacist has reasonable grounds to believe that the preparation is to be used for purposes other than recognized medical or dental purposes.
Methadone (6-dimethylamino-4,4-diphenyl-3-heptanone)
Normethadone (6-dimethylamino-4,4-diphenyl-3-hexanone)
(a) their name or initials; (b) the name, initials and municipal address of the practitioner who issued the order or prescription; (c) the name and municipal address of the person named in the order or prescription; (e) the date on which the narcotic was dispensed; and
Norpipanone (4,4-diphenyl-6-piperidino-3-hexanone)
(a) their name or initials; (b) the name, initials and municipal address of the practitioner who issued the order or prescription; (c) the name and municipal address of the person named in the order or prescription; (e) the directions for use given with the order or prescription; (f) the date on which the verbal prescription narcotic was dispensed; and (g) the number assigned to the order or prescription. File by date and number
Phenadoxone (6-morpholino-4,4-diphenyl-3-heptanone)
Acetyldimethadol (6-dimethylamino-4,4-diphenyl-3-heptanol acetate)
Providing information and assisting inspector (a) furnish such information respecting the dealings of the pharmacist in any narcotic in such form and at such times as the Minister may require; (b) make available and produce to an inspector upon request his special narcotic prescription file together with any books, records or documents which he is required to keep; (c) permit an inspector to make copies of or to take extracts from such files, books, records or documents; and Loss or theft — report
Alphacetylmethadol (α-6-dimethylamino-4,4-diphenyl-3-heptanol acetate)
Alphamethadol (α-6-dimethylamino-4,4-diphenyl-3-heptanol)
Preparing narcotic – approval of formula
Betamethadol (ß-6-dimethylamino-4,4-diphenyl-3-heptanol)
Dimepheptanol (6-dimethylamino-4,4-diphenyl-3-heptanol)
A pharmacist who prepares a narcotic shall, in addition to all other records required to be kept, keep a record of the following: (a) the kind and quantity of any narcotic used in the preparation; (b) the name and quantity of the narcotic prepared; and (c) the date that the prepared narcotic was placed in stock.
Dimenoxadol (dimethylaminomethyl 1-ethoxy-1,1-diphenylacetate)
For the purposes of this section, “prepare” does not include the compounding of a narcotic pursuant to a prescription of a practitioner. Written order
Dioxaphetyl butyrate (ethyl 2,2-diphenyl-4-morpholinobutyrate)
(a) return the narcotic to the licensed dealer who sold or provided it to the pharmacist, if the order is signed and dated by the licensed dealer; or (b) sell or provide to another pharmacist the quantity of the narcotic that is specified in the order as being required for emergency purposes, if the order is signed and dated by the other pharmacist.
Dextropropoxyphene ([S-(R*,S*)]-α-[2-(dimethylamino)-1-methylethyl]-α-phenylbenzeneethanol, propanoate ester)
A pharmacist shall, immediately after returning, selling or providing a narcotic under subsection (1) or after receiving a narcotic under paragraph (1)(b) or subsection 65(4), enter the details of the transaction in a book, register or other record maintained for the purpose of recording such transactions. Notice to Minister
Dextromoramidc (d-1-(3-methyl-4-morpholino-2,2-diphenylbutyryl)pyrrolidine)
A pharmacist shall forthwith after removing, transporting or transferring a narcotic from his place of Communication of Information by Minister to Licensing Authority Contraventions by pharmacist
Diphenylmorpholinoisovaleric acid (2-methyl-3-morpholino-1,1-diphenylpropionic acid)
(a) in the province in which the pharmacist is or was entitled to practise if (i) the authority submits to the Minister a written request that sets out the pharmacist’s name and address, a description of the information being requested and a statement that the information is required for the purpose of assisting a lawful investigation by the authority, or (ii) the Minister has reasonable grounds to believe that the pharmacist has (A) contravened a rule of conduct established by the authority, (B) been convicted of a designated substance offence, or (C) contravened these Regulations; or (b) in a province in which the pharmacist is not entitled to practise, if the authority submits to the Minister (i) a written request that sets out the pharmacist’s name and address and a description of the information being requested, and (ii) a document that shows that (A) the pharmacist has applied to that authority to practise in that province, or (B) the authority has reasonable grounds to believe that the pharmacist is practising in that province without being authorized to do so. Notice of Prohibition of Sale Request by pharmacist
Levomoramidc (l-1-(3-methyl-4-morpholino-2,2-diphenylbutyryl)pyrrolidine)
(a) recipients of the notice must not sell or provide a narcotic, other than a verbal prescription narcotic, to that pharmacist; (b) recipients of the notice must not sell or provide a verbal prescription narcotic, other than a preparation mentioned in section 36, to that pharmacist; and (c) the recipients of the notice must not sell or provide a preparation mentioned in section 36 to that pharmacist. Notice by Minister
Racemoramide (d,l-1-(3-methyl-4-morpholino-2,2-diphenylbutyryl)pyrrolidine)
(b) a verbal prescription narcotic, other than a preparation mentioned in section 36; or (c) a preparation mentioned in section 36.
Buprenorphine (17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-6,14-ethenomorphinan-7-methanol)
The notice must be sent if the pharmacist named in the notice has (a) made a request to the Minister in accordance with section 47 to send the notice; (b) contravened a rule of conduct established by the provincial professional licensing authority of the province in which the pharmacist is practising and the Narcotic Control Regulations Pharmacists Notice of Prohibition of Sale authority has requested the Minister in writing to send the notice; or (c) been convicted of a designated substance offence or of a contravention of these Regulations.
Drotebanol (6ß,14-dihydroxy-3,4-dimethoxy-17-methylmorphinan)
The notice must be sent to (a) all licensed dealers; (b) all pharmacies within the province in which the pharmacist named in the notice is entitled to practice and is practising; (c) the provincial professional licensing authority of the province in which the pharmacist named in the notice is entitled to practise; (d) all pharmacies in an adjacent province in which an order from the pharmacist named in the notice may be filled; and (e) any provincial professional licensing authority in another province that has requested the Minister in writing to send the notice.
Levomethorphan (1-3-methoxy-17-methylmorphinan)
The Minister may send the notice described in subsection (1) to the persons and authorities specified in subsection (3) if the Minister has taken the measures specified in subsection (5) and has reasonable grounds to believe that the pharmacist named in the notice (a) has contravened a provision of the Act or these Regulations; (b) has, on more than one occasion, self-administered a narcotic, other than a verbal prescription narcotic, contrary to accepted pharmaceutical practice; (c) has, on more than one occasion, self-administered a verbal prescription narcotic, other than a preparation mentioned in section 36, contrary to accepted pharmaceutical practice; (d) has, on more than one occasion, provided or administered a narcotic, other than a verbal prescription narcotic, to a person who is a spouse, common-law partner, parent or child of the pharmacist, including a child adopted in fact, contrary to accepted pharmaceutical practice; (e) has, on more than one occasion, provided or administered a verbal prescription narcotic, other than a Narcotic Control Regulations Pharmacists Notice of Prohibition of Sale preparation mentioned in section 36, to a person who is a spouse, common-law partner, parent or child of the pharmacist, including a child adopted in fact, contrary to accepted pharmaceutical practice; or (f) is unable to account for the quantity of narcotic for which the pharmacist was responsible under these Regulations.
Levorphanol (1-3-hydroxy-17-methylmorphinan)
The measures that must be taken before sending the notice are that the Minister has (a) consulted with the provincial professional licensing authority of the province in which the pharmacist to whom the notice relates is entitled to practise; (b) given that pharmacist an opportunity to be heard; and (c) considered (i) the compliance history of the pharmacist in respect of the Act and its regulations, and (ii) whether the actions of the pharmacist pose a risk to public health or safety, including the risk of the narcotic being diverted to an illicit market or use.
Levophenacylmorphan (1-3-hydroxy-17-phenacylmorphinan)
(a) in the circumstance described in paragraph 48(2)(a), the requirements set out in subparagraphs (b)(i) and (ii) have been met and one year has elapsed since the notice was sent by the Minister; or (b) in a circumstance described in any of paragraphs 48(2)(b) and (c) and (4)(a) to (f), the pharmacist named in the notice has (i) requested in writing that a retraction of the notice be sent, and (ii) provided a letter from the provincial professional licensing authority of the province, in which Narcotic Control Regulations Pharmacists Notice of Prohibition of Sale the pharmacist is entitled to practise, in which the authority consents to the retraction of the notice. Restriction
Norlevorphanol (1-3-hydroxymorphinan)
(a) the person or animal is a patient under their professional treatment; and (b) the narcotic is required for the condition for which the person or animal is receiving treatment.
Phenomorphan (3-hydroxy-17-(2-phenylethyl)morphinan)
A practitioner of dentistry or veterinary medicine shall not administer diacetylmorphine (heroin) to an animal or to a person who is not an in-patient or out-patient of a hospital providing care or treatment to persons, and shall not prescribe, sell or provide diacetylmorphine (heroin) for an animal or such a person. Record of narcotics sold or provided
Racemethorphan (d,l-1-3-methoxy-17-methylmorphinan)
and the date on which it was sold or provided, if the quantity of the narcotic exceeds (a) three times the maximum daily dosage recommended by the manufacturer or assembler of the narcotic for that narcotic; or (b) three times the generally recognized maximum daily therapeutic dosage for the narcotic if the manufacturer or assembler has not recommended a maximum daily dosage.
Racemorphan (d, l-3-hydroxy-N-methylmorphinan) Levallorphan (/11-allyl-1,2,3,9,10,10a-hexahydro-4H-10,4a-iminoethanophenanthren-6-ol) and its salts Butorphanol (/N-cyclobutylmethyl-3,14-dihydroxymorphinan) and its salts Nalbuphine (N-cyclobutylmethyl-4,5-epoxy-morphinan-3,6,14-triol) and its salts Phenazocine (1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-phenethyl-2,6-methano-3-benzazocin-8-ol) Metazocine (1,2,3,4,5,6-hexahydro-3,6,11-trimethyl-2,6-methano-3-benzazocin-8-ol) Pentazocine (1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol) Cyclazocine (1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(cyclopropylmethyl)-2,6-methano-3-benzazocin-8-ol) and its salts Diampromide (N-[2-(methylphenethylamino)propyl]propiopropionanilide) Phenampromide (N-(1-methyl-2-piperidino)ethyl)propionanilide) Clonitazene ((p-chlorobenzyl)-2-(diethylaminoethyl)-1-nitro-5-benzimidazole) Etonitazene ((p-ethoxybenzyl)-2-(diethylaminoethyl)-1-nitro-5-benzimidazole) Phencyclidine (phenyl-1 cyclohexyl)-1 piperidine), ses sels, dérivés et analogues, ainsi Propriam
The practitioner shall keep the record in a place, form and manner that will permit an inspector readily to examine and obtain information from it. (a) furnish to the Minister any information that the Minister may require respecting (i) the use by the practitioner of narcotics received — including the administering, selling or providing of them to a person, (ii) the prescriptions for narcotics issued by the practitioner; and (b) produce to an inspector on request any records that these Regulations require the practitioner to keep; (c) permit an inspector to make copies of such records or to take extracts therefrom; (e) retain in his possession for at least two years any record that these Regulations require him to keep; (f) take adequate steps to protect narcotics in his possession from loss or theft; and (g) report to the Minister any loss or theft of a narcotic within 10 days of the practitioner’s discovery of the loss or theft. Communication of Information by Minister to Licensing Authority Contraventions by practitioner
piperidinoethyl)-N-(1-methyl-2- pyridyl)propanamide)
(a) in the province in which the practitioner is or was registered and entitled to practise if (i) the authority submits to the Minister a written request that sets out the practitioner’s name and address, a description of the information being requested and a statement that the information is required for the purpose of assisting a lawful investigation by the authority, or (ii) the Minister has reasonable grounds to believe that the practitioner has (A) contravened a rule of conduct established by the authority, (B) been convicted of a designated substance offence, or (C) contravened these Regulations; or (b) in a province in which the practitioner is not registered and entitled to practise, if the authority submits to the Minister (i) a written request that sets out the practitioner’s name and address and a description of the information being requested, and (ii) a document that shows that (A) the practitioner has applied to that authority to practise in that province, or (B) the authority has reasonable grounds to believe that the practitioner is practising in that province without being authorized to do so. Notice of Prohibition of Sale Request by practitioner
Clonitazene (2-[p-chlorobenzyl]-1- diethylaminoethyl-5- nitrobenzimidazole)
(a) recipients of the notice must not sell or provide a narcotic, other than a verbal prescription narcotic, to that practitioner; (c) pharmacists practising in the notified pharmacies must not fill a prescription or order for a narcotic, other than a verbal prescription narcotic, written by that practitioner; Notice by Minister
Etonitazene (2-[p-ethoxybenzyl]-1- diethylaminoethyl-5- nitrobenzimidazole) 14 Phencyclidine (1-(1- phenylcyclohexyl)piperidine), its salts,
(a) pharmacists practising in the notified pharmacies and licensed dealers must not sell or provide to the practitioner named in the notice a narcotic other than a verbal prescription narcotic or a verbal prescription narcotic; (b) pharmacists practising in the notified pharmacies must not fill a prescription or order from the practitioner named in the notice for a narcotic other than a verbal prescription narcotic or a verbal prescription narcotic; or (c) the prohibitions in both paragraphs (a) and (b) apply with respect to the practitioner named in the notice.
Ketamine (2-(2-chlorophenyl)-2- (methylamino)cyclohexanone)
The notice must be sent if the practitioner named in the notice has (a) made a request to the Minister in accordance with section 58 to send the notice; (b) contravened a rule of conduct established by the provincial professional licensing authority of the province in which the practitioner is practising and the authority has requested the Minister in writing to send the notice; or (c) been convicted of a designated substance offence or of a contravention of these Regulations.
Acetyl-α-methylfentanyl (N-[1-(α- methylphenethyl)-4- piperidyl]acetamide)
The notice must be sent to (a) all licensed dealers; (b) all pharmacies within the province in which the practitioner named in the notice is registered and entitled to practise and is practising; (c) the provincial professional licensing authority of the province in which the practitioner named in the notice is registered and entitled to practise; (d) all pharmacies in an adjacent province in which a prescription or order from the practitioner named in the notice may be filled; and (e) any provincial professional licensing authority in another province that has requested the Minister in writing to send the notice.
Alfentanil (N-[1-[2-(4-ethyl-4,5- dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4- (methoxymethyl)-4- piperidyl]propanamide)
The Minister may send the notice described in subsection (1) to the persons and authorities specified in subsection (3) if the Minister has taken the measures specified in subsection (5) and has reasonable grounds to believe that the practitioner named in the notice (a) has contravened a provision of the Act or these Regulations; (b) has, on more than one occasion, self-administered a narcotic, other than a verbal prescription narcotic, under a self-directed prescription or order or, in the absence of a prescription or order, contrary to accepted professional practice; (c) has, on more than one occasion, self-administered a verbal prescription narcotic under a self-directed prescription or order or, in the absence of a prescription or order, contrary to accepted professional practice; (d) has, on more than one occasion, prescribed, provided or administered a narcotic, other than a verbal prescription narcotic, to a person who is a spouse, common-law partner, parent or child of the practitioner, including a child adopted in fact, contrary to accepted professional practice; (e) has, on more than one occasion, prescribed, provided or administered a verbal prescription narcotic to a person who is a spouse, common-law partner, parent or child of the practitioner, including a child adopted in fact, contrary to accepted professional practice; or (f) is unable to account for the quantity of narcotic for which the practitioner was responsible under these Regulations.
Carfentanil (methyl 4-[1- (oxopropyl)phenylamino]-1- (2-phenylethyl)-4-piperidinecarboxylate)
The measures that must be taken before sending the notice are that the Minister has (a) consulted with the provincial professional licensing authority of the province in which the practitioner to whom the notice relates is registered and entitled to practise; (b) given that practitioner an opportunity to be heard; and (c) considered (i) the compliance history of the practitioner in respect of the Act and its regulations, and (ii) whether the actions of the practitioner pose a risk to public health or safety, including the risk of the narcotic being diverted to an illicit market or use.
p-Fluorofentanyl (4′ fluoro-N-(1- phenethyl-4-piperidyl) propionanilide)
authorities who were sent a notice under subsection 59(1) with a notice of retraction of that notice if (a) in the circumstance described in paragraph 59(2)(a), the requirements set out in subparagraphs (b)(i) and (ii) have been met and one year has elapsed since the notice was sent by the Minister; or (b) in a circumstance described in any of paragraphs 59(2)(b) and (c) and (4)(a) to (f), the practitioner named in the notice has (i) requested in writing that a retraction of the notice be sent, and (ii) provided a letter from the provincial professional licensing authority of the province in which the practitioner is registered and entitled to practice in which the authority consents to the retraction of the notice.
Fentanyl (N-(1-phenethyl-4- piperidyl)propionanilide)
(a) keep or cause to be kept in a book, register or other record maintained for such purposes, (i) the name and quantity of any narcotic received, (ii) the name and address of the person from whom any narcotic was received and the date received, (iii) the name and quantity of any narcotic used in the making or assembling of a product or compound containing that narcotic, (iv) the name and quantity of any product or compound that was made or assembled and that contains that narcotic and the date on which the product or compound was made or assembled, (v) the name of the patient for whom a narcotic, other than dextropropoxyphene or a verbal prescription narcotic, was dispensed, (vii) the date a narcotic, other than dextropropoxyphene or a verbal prescription narcotic was ordered or prescribed and the form and quantity thereof; b) maintain the recorded information in such form as to enable an audit to be made from time to time for a period of not less than two years from the making thereof; c) take all necessary steps to protect narcotics in the hospital against loss or theft, and report to the Minister any loss or theft of narcotics within 10 days of his discovery thereof. Providing information and assisting inspector
ß-Hydroxyfentanyl (N-[1-(ß- hydroxyphenethyl)-4- piperidyl] propionanilide)
a) furnish such information respecting the use of narcotics therein, in such form and at such times as the Minister may require; b) produce to an inspector any books, records or documents required by these Regulations to be kept; c) permit an inspector to make copies thereof or take extracts from such books, records and documents; and Selling, providing or administering narcotic
ß-Hydroxy-3-methylfentanyl (N-[1-(ß- hydroxyphenethyl)-3-methyl-4- piperidyl] propionanilide)
α-Methylfentanyl (N-[1-(α- methylphenethyl)-4- piperidyl] propionanilide)
On receipt of a written order or prescription signed and dated by a practitioner, the person in charge of a hospital may permit a narcotic, other than diacetylmorphine (heroin), to be administered to a person or an animal under treatment as an in-patient or out-patient of the hospital, or to be sold or provided for the person or to the person in charge of the animal. (2.1) On receipt of a verbal prescription given by a practitioner, the person in charge of a hospital may permit a verbal prescription narcotic to be administered to a person or an animal under treatment as an in-patient or out-patient of the hospital, or to be sold or provided for the person or to the person in charge of the animal. Emergency — other hospital
α-Methylthiofentanyl (N-[1-[1- propionanilide)
Subject to subsection (5.1), the person in charge of a hospital may permit a narcotic to be provided, for emergency purposes, to a hospital employee or practitioner in another hospital on receipt of a written order signed and dated by a pharmacist in the other hospital or a practitioner authorized by the person in charge of the other hospital to sign the order.
3-Methylfentanyl (N-(3-methyl-1- phenethyl-4-piperidyl) propionanilide)
Subject to subsection (5.1), the person in charge of a hospital may permit a narcotic to be sold or provided, for emergency purposes, to a pharmacist on receipt of a written order signed and dated by the pharmacist. (5.1) No person in charge of a hospital shall permit a narcotic to be sold or provided under subsection (3) or (4) unless the signature of the pharmacist in the other hospital or of the practitioner authorized by the person in charge of the other hospital to sign an order is known to the person who sells or provides the narcotic or has been verified. Research purposes
3-Methylthiofentanyl (N-[1-[1- propionanilide) (11.1) Remifentanil (methyl 4-[ [oxo-1 propyl) phenylamino]-4- piperidinepropanoate)
A person in charge of a hospital may permit a narcotic to be provided to a person who is exempted under section 56 of the Act with respect to the possession of the narcotic and who is employed in a research laboratory in the hospital for the purpose of research.
Sufentanil (N-[1-[methoxtymethyl)-4- propionanilide)
The person in charge of a hospital may permit diacetylmorphine (heroin) to be sold, provided or administered to a person under treatment as an in-patient or out-patient of the hospital on receipt of a written order or Narcotic Control Regulations prescription signed and dated by a practitioner of medicine or dentistry or a nurse practitioner. General
Thiofentanyl (N-[[thiophen-2)-2] ethyl]-1 piperidyl-4] propionanilide)
Identification or analysis of narcotic
3-Methylthiofentanyl (N-[3-methyl-1-[2-(2-thienyl)ethyl]-4-piperidyl] propionanilide) (11.1) Remifentanil (dimethyl 4-carboxy-4-(N-phenylpropanamido)-1-piperidinepropionate)
(b) an agent or mandatary of a practitioner of medicine, if the agent or mandatary is exempted under section 56 of the Act with respect to the possession of that narcotic for that purpose.
Sufentanil (N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidyl] propionanilide)
An agent or mandatary of a practitioner of medicine who receives the narcotic must immediately provide or deliver it to
Thiofentanyl (N-[1-[2-(2-thienyl)ethyl]-4-piperidyl] propionanilide) 17 [Repealed, SOR/2018-147, s. 28] (i) Nabilone ((±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one) (ii) parahexyl (3-hexyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-ol) (iii) 3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol (DMHP) (iv) 5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol (CP 55,940) SCHEDULE (ii) Parahexyl (3-hexyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-ol) (iii) 3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol (DMHP) (iv) 5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol (CP 55,940) (v) 5-(1,1-dimethylheptyl)-2-(3-hydroxycyclohexyl)phenol (CP 47,497) (i) 1-pentyl-3-(1-naphthoyl)indole (JWH-018) (ii) 1-butyl-3-(1-naphthoyl)indole (JWH-073) (iii) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) (iv) 1-hexyl-3-(1-naphthoyl)indole (JWH-019) (v) 1-(4-pentenyl)-3-(1-naphthoyl)indole (JWH-022) (vi) 1-butyl-3-(4-methoxy-1-naphthoyl)indole (JWH-080) (vii) 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081) (viii) 1-(2-morpholin-4-ylethyl)-3-(1-naphthoyl)indole (JWH-200) (ix) 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210) (x) 1-pentyl-3-(2-methoxy-1-naphthoyl)indole (JWH-267) (xi) 1-[(N-methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole (AM-1220) (xii) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201) (xiii) 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole (MAM-2201) Règlement sur les stupéfiants ANNEXE (v) 5-(1,1-diméthylheptyl)-2-(3-hydroxycyclohexyl)phénol (CP 47,497)
A practitioner of medicine who receives the narcotic must immediately provide or deliver it (a) for the purpose of its identification or analysis, to a person who is exempted under section 56 of the Act with respect to the possession of that narcotic for that purpose; or Records — person who is exempted or who has received a narcotic for the purpose of identification or analysis
toute substance ayant une structure 3-(1-naphthoyl)indole substituée à l’atome d’azote du cycle indole, qu’il y ait ou non davantage de substitution sur ce cycle indole, qu’il y ait ou non substitution sur le cycle naphthyle dans quelque mesure que ce soit, notamment : (i) 1-pentyl-3-(1-naphthoyl)indole (JWH-018) (ii) 1-butyl-3-(1-naphthoyl)indole (JWH-073) (iii) 1-pentyl-3-(4-méthyl-1-naphthoyl)indole (JWH-122) (iv) 1-hexyl-3-(1-naphthoyl)indole (JWH-019) (v) 1-(4-pentényl)-3-(1-naphthoyl)indole (JWH-022) (vi) 1-butyl-3-(4-méthoxy-1-naphthoyl)indole (JWH-080) (vii) 1-pentyl-3-(4-méthoxy-1-naphthoyl)indole (JWH-081) (viii) 1-(2-morpholin-4-yléthyl)-3-(1-naphthoyl)indole (JWH-200) (ix) 1-pentyl-3-(4-éthyl-1-naphthoyl)indole (JWH-210) (x) 1-pentyl-3-(2-méthoxy-1-naphthoyl)indole (JWH-267) (xi) 1-[(N-méthylpipéridin-2-yl)méthyl]-3-(1-naphthoyl)indole (AM-1220) (xii) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201) (xiii) 1-(5-fluoropentyl)-3-(4-méthyl-1-naphthoyl)indole (MAM-2201) (xiv) 1-(5-fluoropentyl)-3-(4-éthyl-1-naphthoyl)indole (EAM-2201) (xv) 2-(2,3-dihydro-5-méthyl-3-(4-morpholinylméthyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl)-1-naphthalenyl-méthanone (WIN 55,212-2)
(a) keep a record of the following information for a two-year period beginning on the day on which the record is made (i) the name and quantity of any narcotic purchased or received by them and the date on which it was purchased or received, (ii) the name and address of the person from whom the narcotic was purchased or received, and (iii) particulars of the use to which the narcotic was put; (b) provide any information respecting the narcotic that the Minister may require; and (c) permit access to the records that are required to be kept by these Regulations. Advertising
toute substance ayant une structure 3-(1-naphthoylpyrrole substituée à l’atome d’azote du cycle pyrrole, qu’il y ait ou non davantage de substitution sur ce cycle dans quelque mesure que (xiv) 1-(5-fluoropentyl)-3-(4-ethyl-1-naphthoyl)indole (EAM-2201) (xv) ((3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl)-1-naphthalenyl-methanone (WIN 55,212-2) (i) 1-pentyl-5-(2-fluorophenyl)-3-(1-naphthoyl)pyrrole (JWH-307) (i) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) (ii) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251) (iii) 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302) (i) 1-(1-methylpiperidin-2-ylmethyl)-3-(2-iodobenzoyl)indole (AM-2233) (i) 1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (UR-144) (ii) 1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (5F-UR-144) (i) (1-pentyl-1H-indol-3-yl)(2,2,3,3- tetramethylcyclopropyl)- methanone (UR-144) (ii) (1-(5-fluoropentyl)-1H-indol-3- yl)(2,2,3,3- tetramethylcyclopropyl)- methanone (5F-UR-144) (iii) (1-(2-(4-morpholinyl)ethyl)-1H- indol-3-yl)(2,2,3,3- tetramethylcyclopropyl)- methanone (A-796,260) (i) 1-pentyl-8-quinolinyl ester-1H- indole-3-carboxylic acid (PB-22) (ii) 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (5F-PB-22) (i) N-(adamantan-1-yl)-1-pentyl-1H- indazole-3-carboxamide (AKB48) (ii) N-(adamantan-1-yl)-1-(5- fluoropentyl)-1H-indazole-3- carboxamide (5F-AKB48) (iii) N-(1-(aminocarbonyl)-2- methylpropyl)-1-(4- fluorobenzyl)-1H-indazole-3- carboxamide (AB-FUBINACA) (iv) N-(1-amino-3-methyl-1- oxobutan-2-yl)-1-pentyl-1H- indazole-3-carboxamide (AB- PINACA) (i) N-(adamantan-1-yl)-1- fluoroethylindole-3- carboxamide (STS-135) (i) N-(adamantan-1-yl)-1-fluoropentylindole-3-carboxamide (STS-135) (ii) N-(adamantan-1-yl)-1-pentylindole-3-carboxamide (APICA)
(b) advertise a preparation referred to in section 36 in a pharmacy; or (c) publish any written advertisement respecting a narcotic unless that advertisement displays the symbol “N” in a clear and conspicuous colour and size in the upper left quarter of its first page. Notification of application for order of restoration
O-desmethyltramadol (3-[2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]-phenol)
(a) the name of the justice to whom the application is to be made; (b) the time and place at which the application is to be heard; (c) details concerning the narcotic or other thing in respect of which the application is to be made; and (d) the evidence on which the applicant intends to rely to establish that they are entitled to possession of the narcotic or other thing referred to in paragraph (c). Communication of information by Minister to nursing statutory body
N,O-didesmethyltramadol (3-[1-hydroxy-2-[(methylamino)methyl]cyclohexyl]-phenol)
Non-application
2-methyl-AP-237 (1-(4-cinnamyl-2-methylpiperazin-1-yl)butan-1-one)
Subsection (1) does not apply to a nurse practitioner.
para-methyl-AP-237 ((E)-1-(4-(3-(p-tolyl)allyl)piperazin-1-yl)butan-1-one)
The following definitions apply in this section. member means any person who is authorized by a nursing statutory body to practice nursing. (membre) nursing statutory body means any provincial professional licensing authority that, in accordance with the laws of that province, authorizes a person to practise nursing. (organisme régissant la profession d’infirmier) Exemption — member of police force
AP-238 (1-(4-cinnamyl-2,6-dimethylpiperazin-1-yl)propan-1-one) SOR/97-227, s. 5; SOR/98-185, s. 1; SOR/99-373, s. 12; SOR/2000-244, s. 11(E); SOR/2003-93, s. 1; SOR/2005-272, s. 1; SOR/2013-172, s. 8; SOR/2015-118, s. 1; SOR/2015-301, ss. 1, 2; SOR/2016-230, ss. 72, 73; SOR/2017-18, ss. 25 to 29; SOR/2017-276, s. 1; SOR/2018-85, ss. 72, 73; SOR/2018-147, s. 28; SOR/2019-120, s. 1; SOR/2019-169, s. 28; SOR/2021-43, s. 1; SOR/2024-99, s. 1. RELATED PROVISIONS — SOR/2012-230, s. 28 Definition Application Former Regulations — para. 36(1)(b) — SOR/2013-172, s. 13 Règlement sur les stupéfiants DISPOSITIONS CONNEXES — DORS/2012-230, art. 28 Définition 28 (1) Au présent article, règlement antérieur s’entend du Règlement sur les stupéfiants, dans sa version antérieure à l’entrée en vigueur du présent règlement. Application
of the member or person, is exempt from the application of subsection 4(2) or section 5, 6 or 7 of the Act by virtue of the Controlled Drugs and Substances Act (Police Enforcement) Regulations is, in respect of that conduct, exempt from the application of these Regulations.
Le présent article s’applique à la préparation visée par l’article 36 du règlement antérieur. Règlement antérieur — al. 36(1)(b)
and the salts, derivatives and salts of derivatives of the substances set out in subitems (1) to (4), including: but not including
Malgré le présent règlement, si la partie principale de l’étiquette ou de tout contenant extérieur de la préparation contient l’information prévue à l’alinéa 36(1)(b) du règlement antérieur, cet alinéa continue de s’appliquer à la partie principale de l’étiquette ou de tout contenant extérieur pendant la période de six mois suivant la date de la publication du présent règlement dans la Partie II de la Gazette du Canada. — DORS/2013-172, art. 13 13 Pour l’application de l’alinéa 11(2)(a) de la Loi sur les textes réglementaires, le présent règlement prend effet avant sa publication dans la Gazette du Canada.
Narcotine (6,7-dimethoxy-3-[5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo [4,5-g]isoquinolin-5-yl]-1(3H)-isobenzofuranone) and its salts
Papaverine (1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline) and its salts
but not including
Betameprodine (ß-3-ethyl-1-methyl-4-phenyl-4-piperidinol propionate) Methylphenylisonipecotonitrile (4-cyano-1-methyl-4-phenylpiperidine) Properidine (isopropyl 1-methyl-4-phenylpiperidine-4-carboxylate) Trimeperidine (1,2,5-trimethyl-4-phenyl-4-piperidinol propionate) Pethidine Intermediate C (1-methyl-4-phenylpiperidine-4-carboxylate) but not including Carperidine (ethyl 1-(2-carbamylethyl)-4-phenylpiperidine-4-carboxylate) and its salts Oxpheneridine (ethyl 1-(2-hydroxy-2-phenylethyl)-4-phenylpiperidine-4-carboxylate) and its salts
Proheptazine (hexahydro-1,3-dimethyl-4-phenyl-1Hazepin-4-ol propionate) but not including Ethoheptazine (ethyl hexahydro-1-methyl-4-phenylazepine-4-carboxylate) and its salts Metoheptazine (ethyl hexahydro-1,3-dimethyl-4-phenylazepine-4-carboxylate) and its salts Methoheptazine (methylhexahydro-1,2-dimethyl-4-phenylazepine-4-carboxylate) and its salts
Isomethadone (6-dimethylamino-5-methyl-4,4-diphenyl-3-hexanone)
Betacetylmethadol (ß-6-dimethylamino-4,4-diphenyl-3-heptanol acetate)
Noracymethadol (α-6-methylamino-4,4-diphenyl-3-heptanol acetate)
Diethylthiambutene (N,N-diethyl-1-methyl-3,3-di-2-thienylallylamine)
Dimethylthiambutene (N,N,1-trimethyl-3,3-di-2-thienylallylamine)
Ethylmethylthiambutene (N-ethyl-N,1-dimethyl-3,3-di-2-thienylallylamine)
but not including Dextromethorphan (d-1,2,3,9,10,10a-hexahydro-6-methoxy-11-methyl-4H-10,4a-iminoethanophenanthren) and its salts Dextrorphan (d-1,2,3,9,10,10a-hexahydro-11-methyl-4H-10,4a-iminoethanophenanthren-6-ol) and its salts Levorphan (/11-propargyl-1,2,3,9,10,10a-hexahydro-4H-10,4a-iminoethanophenanthren-6-ol) and its salts Benzazocines, their salts, derivatives and salts of derivatives, including: but not including Ampromides, their salts, derivatives and salts of derivatives, including: Benzimidazoles, their salts and derivatives, including:
of derivatives, including: derivatives and analogues and salts of derivatives and analogues, including:
analogues and salts of derivatives and analogues, including: methyl-2-(2-thienyl)ethyl]-4-piperidyl] methyl-2-(2-thienyl)ethyl]-4-piperidyl] [(thiophen-2)-2] ethyl]-1- piperidyl-4]
Any substance that has a 2-(cyclohexyl)phenol structure with substitution at the 1-position of the benzene ring by a hydroxy, ether or ester group and further substituted at the 5-position of the benzene ring, whether or not further substituted on the benzene ring to any extent, and substituted at the 3'-position of the cyclohexyl ring by an alkyl, carbonyl, hydroxyl, ether or ester, and whether or not further substituted on the cyclohexyl ring to any extent, including Narcotic Control Regulations
Any substance that has a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent, including
Any substance that has a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted on the pyrrole ring to any extent and whether or not substituted on the naphthyl ring to any extent, including
Any substance that has a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the phenyl ring to any extent, including
Any substance that has a 3-benzoylindole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the phenyl ring to any extent, including
Any substance that has a 3-methanone(cyclopropyl)indole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the cyclopropyl ring to any extent, including cyclopropyl ring to any extent, including
Any substance that has a quinolin-8-yl 1H-indole-3-carboxylate structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the quinolin-8-yl ring to any extent, including
Any substance that has a 3- carboxamidoindazole structure with substitution at the nitrogen atom of the indazole ring, whether or not further substituted on the indazole ring to any extent and whether or not substituted at the carboxamide group to any extent, including
Any substance that has a 3- carboxamidoindole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, including extent and whether or not substituted at the carboxamide group to any extent, including
Narcotic Control Regulations
This section applies to a preparation referred to in section 36 of the former Regulations.
Despite these Regulations, if the main panel of the label of a preparation or any outer container of the preparation displays information in accordance with paragraph 36(1)(b) of the former Regulations, that paragraph continues to apply to the main panel of the label or outer container during the period of six months after the day on which these Regulations are published in the Canada Gazette, Part II.